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Abstract  
Intrahepatic cholestasis in pregnancy (ICP) is characterized by raised serum bile acids 
which can cause fetal complications, including preterm labour and intrauterine death. 
The fetal death in ICP is not well understood. In this thesis, the mechanisms of bile-acid 
induced arrhythmia were studied extensively using in vitro models of the fetal heart.  
Addition of the bile acid taurocholate (TC) to cardiomyocytes led to a reduction in the 
rate and amplitude of contraction, dysregulation of beating and desynchronization of 
intracellular calcium release. The results obtained from both differentiated mouse and 
human embryonic stem cell-derived cardiomyocytes (ESC-CM) demonstrated that 
immature cardiomyocytes are more susceptible to TC-induced arrhythmias than more 
mature cardiomyocytes.  
Although classical hepatic bile acid transporters such as ntcp, mrp2 and mdr2 are 
expressed in neonatal rat cardiomyocytes, the results suggest that they are unlikely to 
play role in TC-induced arrhythmia. They also suggest that the bile acid nuclear 
receptor FXR is not involved as uptake of radioactively labelled TC into the cells is 
minimal and that there is no functional involvement of the classical hepatic FXR 
pathways in neonatal rat cardiomyocytes. Similarly, the membrane bile acid receptor 
TGR5 showed neither immunoreactivity nor functional effects in cardiomyocytes.  
TC binds to the muscarinic M2 receptor and serves as a partial agonist of this receptor in 
terms of receptor activation and its inhibitory effect on cAMP in neonatal rat 
cardiomyocytes. Inhibition of the M2 muscarinic receptor by antagonist and the 
knockdown of the receptor with siRNA completely abolished the negative effect of TC 
on cardiomyocyte contraction, calcium transient amplitude and synchronisation in small 
cell clusters.  
In conclusion, immature ESC-CMs are more susceptible to TC and this effect is lost as 
cells progress to more mature phenotypes. Moreover, the findings suggest the 
arrhythmogenic effect of TC in neonatal cardiomyocytes is mediated by the muscarinic 
M2 receptor. This mechanism might serve as a promising new therapeutic target for fetal 
arrhythmia. 
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1 Introduction 
 
1.1 Overview 
 
Intrahepatic cholestasis in pregnancy (ICP) is a liver disease of pregnancy which is 
characterised by raised serum bile acids. This disease can be complicated by fetal 
distress, intrauterine death and pre-term labour. In addition, fetal complications have 
been reported to be more common when the maternal total serum bile acid level is >40 
µmol/L. The aetiology of fetal death is not well understood. There is no evidence of 
utero-placental insufficiency and placental histology shows non-specific changes. 
However, studies of the fetal heart in ICP have demonstrated an abnormal fetal heart 
rate and arrhythmias.  
 
This thesis aims to provide experimental evidence related to possible mechanisms of 
fetal death in ICP. The first part of the introduction will focus on ICP and its relevance. 
The second part of the introduction will describe bile acids and their signalling 
pathways that are of relevance to the findings presented in this thesis. Finally, the 
modulation of cardiac contraction and models of the fetal heart will be reviewed in this 
chapter.  
 
1.2 Intrahepatic cholestasis of pregnancy (ICP) 
 
The aetiology of this disease is believed to be multifactorial and it is not completely 
understood (Lammert et al. 2000). ICP is a condition that can affect both the fetus and 
the mother during pregnancy. However ICP can be life-threatening to the fetus. It has 
been reported that ICP can increase adverse fetal outcomes such as intrauterine death, 
fetal distress and spontaneous pre-term labour (Fisk & Storey 1988, Rioseco et al. 1994, 
Glantz et al. 2004). In the mother the principal clinical symptom is pruritus and 
abnormal liver function which resolves following delivery (Williamson et al. 2004, 
Berg et al. 1986). In ICP, serum total bile acids can increase 100 times above the normal 
range (Laatikainen T 1977).  
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1.2.1 Epidemiology and aetiology 
 
The incidence of ICP varies according to geographical region and ethnic background. It 
has been reported to be most common in South America, particularly Chile (Reyes 
1982), with higher rates of ICP incidence seen in women who are of Araucanian Indian 
Descent. The prevalence has reduced in recent years from 14% of deliveries in 1975 to 
4% in 1995 (Reyes 1997). In Europe ICP is considered uncommon (approximately 
0.1% to 0.2% of pregnancies) with the highest rates reported in Scandinavian countries 
(Savander et al. 2003). ICP affects 0.7% of pregnancies in the UK (Kenyon et al. 2002). 
ICP is also influenced by seasonal variation and is more common during winter, as has 
been reported in Finland, Sweden, Chile and Portugal (Berg et al. 1986, Brites et al. 
1998). 
 
The aetiology of ICP has been reported to be heterogenous with hormonal, genetic and 
environmental factors having important roles. Hormonal factors have been suggested to 
play key roles in the aetiology of ICP as the disease starts in late trimester of pregnancy 
when progesterone (Bacq et al. 1997) and estrogen (Barth et al. 2003) levels are highest. 
Moreover, ICP is more common in twin pregnancies as the hormone levels rise more 
than in single pregnancies (Gonzalez et al. 1989). ICP symptoms may also reappear in a 
subgroup of women with history of ICP when taking the combined oral contraceptive 
pill (Williamson et al. 2004). The incidence of ICP has been reported to be higher in 
patients with mothers and sisters who have a history of ICP (Hirvioja & Kivinen 1993).  
The second factor that has been suggested to play a role in the aetiology of ICP is 
genetic variability. Recent research on the involvement of genetic factors in ICP has 
focused on the role of mutations in specific genes encoding biliary transport proteins. 
Current data have shown that a subgroup of patients with ICP have mutations in the 
genes encoding the bile transporting proteins BSEP and MDR3 (Pauli-Magnus et al. 
2005, Dixon & Williamson 2008, Pauli-Magnus et al. 2004, Dixon et al. 2000). In 
addition, there are data from smaller studies suggesting that genetic variation in other 
ATP binding cassette (ABC) transporters may also be associated with ICP (Sookoian et 
al. 2008, Lammert et al. 2000). Genetic variation of the farnesoid X receptor (FXR), the 
nuclear receptor and bile acid sensor, has also been found to be associated with ICP 
(van Mil et al. 2007). Finally, environmental factors are thought to play a role in the 
aetiology of ICP; factors such as seasonal variation and dietary selenium intake have 
been shown to be associated with ICP prevalence. ICP is more common during winter 
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months in Chile and Scandinavia.  Although several environmental factors have been 
studied, the definitive correlation of ICP incidence with these factors is currently 
unknown.  
 
1.2.2 Clinical and Biochemical features 
 
The defining clinical feature that distinguishes ICP from other liver diseases of 
pregnancy is pruritus, which presents in 80% of patients after 30 weeks of gestation 
(Kenyon et al. 2002, Reyes 1992) and occasionally presents as early as 8 weeks (Berg et 
al. 1986). ICP usually disappears within 48 hours of delivery and has been reported to 
typically recur in subsequent pregnancies. Pruritus can affect all parts of the body but 
most frequently affects the palms of the hands and soles of the feet. However it is not 
associated with dermatological lesions. ICP can occasionally present with jaundice 
(Bacq et al. 1997) and steatorrhea (Reyes 1982, Mullally 2002). Jaundice occurs in 10 
to 15% cases of ICP and develops after 1 to 4 weeks after the pruritus (Knox & Olans 
1996, Nichols 2005).  
 
Serum bile acid measurement is the most appropriate biochemical marker to diagnose 
and monitor ICP. In ICP patients, the serum primary bile acids cholic acid (CA) and 
chenodeoxycholic acid (CDCA) profiles are different to those observed in normal 
pregnancy. ICP primary bile acid CA and CDCA levels are significantly raised when 
compared to levels of the secondary bile acid deoxycholic acid (Laatikainen T 1977). 
Moreover, taurine conjugated bile acids can increase up to 5 fold more than glycine 
conjugated bile acids (Heikkinen et al. 1983). However, it has been suggested that the 
rise in serum bile acids does not necessarily lead to the onset of symptoms. Another 
important biochemical measurement used to diagnose ICP is the liver function test 
alanine transaminase (ALT), which is a marker of liver damage.  
The clinician‟s prime concern during ICP is the possibility of adverse fetal outcomes. 
The prognosis of this disorder is usually good for the mother as the condition resolves 
promptly after delivery. However, clinical studies of ICP pregnancies have shown that 
fetal complications occur more commonly when the maternal bile acids are more than 
40µmol/L, and in this group of patients, premature delivery occurs in up to 16.7% of 
cases, fetal asphyxia occurs in up to 13.5% cases, meconium staining of amniotic fluid 
complicates 44% of cases and fetal loss can occur in 0.4% to 4.1% cases (Glantz et al. 
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2004). Intrauterine death affected approximately 10% of ICP pregnancies in older 
studies (Reid et al. 1976, Reyes 1982). In more recent studies it affects approximately 
1% of cases (Lammert et al. 2000). Intrauterine death is thought to occur suddenly, as 
there is no evidence of preceding intrauterine growth restriction or utero-placental 
insufficiency and the fetal autopsy is normal (Fisk & Storey 1988). An abnormal fetal 
heart rate ( 100 or 180 beats/minute) has been observed in previous studies 
(Laatikainen 1975, Reid et al. 1976, Laatikainen & Tulenheimo 1984) and it has been 
proposed that fetal arrhythmia may be the cause of fetal death in ICP (Williamson et al. 
2001).  
 
1.2.3 Management of ICP 
 
Ursodeoxycholic acid (UDCA) is the major bile acid species in bears, whereas in 
human it constitutes only 3% of the total bile acids produced. UDCA has been shown to 
protect rat and human hepatocytes against membrane damage and the cytotoxic effects 
of hydrophobic bile acids (Heuman & Bajaj 1994, Benz et al. 1998). The management 
of ICP varies around the world. Nevertheless, the aim of ICP management is to reduce 
serum bile acid levels and symptoms in the mother in order to reduce the risk of fetal 
complications. Treatment with the hydrophilic bile acid, UDCA has been shown to 
improve pruritus and reduce the serum bile acid levels of the mother and fetus in ICP 
(Glantz et al. 2005). Moreover, no fetal morbidity and mortality have been reported 
after UDCA treatment in ICP. UDCA has been demonstrated to increase the expression 
of transporter proteins that are involved in biliary secretion in the liver of human and 
experimental animals (Beuers 2006, Marschall et al. 2005).  
 
Other drugs that have been shown to be effective in reducing serum bile acids in ICP 
include dexamethasone, rifampicin and S-Adenosyl-L-methionine (SAMe) (Glantz et 
al. 2005, Hirvioja et al. 1992). However, a recent study has reported that UDCA is more 
effective than dexamethasone at reducing bile acids and bilirubin levels in ICP patients 
(Glantz et al. 2005). Rifampicin is widely used in several other liver diseases and also 
has been shown to cause a reduction in serum total bile acids in ICP. In addition, 
rifampicin has been shown to cause a decrease in serum transaminases and 
improvement in pruritus in ICP. A clinical trial that compared UDCA and SAMe 
reported that UDCA is more effective in reducing serum bile acids and improving liver 
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function test results (Roncaglia et al. 2004). So far, UDCA has been reported to be the 
most effective drug for treatment of ICP (Roncaglia et al. 2004, Glantz et al. 2005). 
 
1.3 Bile acids  
 
Bile acids are steroidal detergent molecules that normally possess 1, 2 or 3 hydroxyl 
groups. Every day approximately 500 mg of bile acids are de novo synthesized from 
cholesterol in the hepatocytes of the adult human liver and secreted into the bile 
canaliculus and then stored in the gall bladder. Bile acid circulation involves the liver, 
bile duct, small intestine and portal vein which collectively form the enterohepatic 
circuit (Houten & Auwerx 2004). Upon ingestion of a meal, bile acids are secreted from 
bile ducts into the small intestine where they serve as emulsifiers of dietary cholesterol, 
lipids and fat soluble vitamins. Approximately 95% of secreted bile acids are 
reabsorbed by the large intestine and transported back to the liver via the portal 
circulation (Lefebvre et al. 2009). The remaining 5% of bile acids are excreted into the 
faeces. 
 
1.3.1 Bile acids and their chemical characteristics 
 
Bile acids are cytotoxic as they have detergent properties and therefore their synthesis is 
highly regulated. They consist of a steroid nucleus and aliphatic side chain. Bile acids 
are also known as amphipathic molecules as they contain both a hydrophobic (β-face) 
and hydrophilic side (α-face). Bile acids that are synthesized in the liver are known as 
primary bile acids. Cholic acid (CA) and chenodeoxycholic acid (CDCA) are the most 
common primary bile acids. CA consists of 3 hydroxy groups at C-3, C-7 and C-12, 
whereas CDCA consists of 2 hydroxy groups at C-3 and C-7 (Figure 1.1). When these 
primary bile acids leave hepatocytes, the majority of them are conjugated and acquire 
the ability to form micelles with lipids.  
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Figure 1. 1: Common chemical structures of bile acids. 
Hydroxyl groups at position Carbon-6 and Carbon-12 are in α-orientation, whereas 
hydroxyl group at position Carbon-7 is in β-orientation. 
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Bile acids that are modified by the anaerobic bacteria in the colon are known as 
secondary bile acids. When primary bile acids enter the colon, the hydroxyl group at C-
7 is removed by anaerobic bacteria thus forming 7-deoxy bile acids. The most common 
secondary bile acids are lithocholic acid (LCA) formed from CDCA and deoxycholic 
acid (DCA) formed from CA. The biliary bile acid pool consists mainly of conjugated 
CA and CDCA and about 10% conjugated DCA. Only low concentrations of LCA are 
present in the biliary bile acid pool.  
 
The secondary bile acids are absorbed by the colon and return to the liver, where they 
may be structurally altered by conjugation with taurine or glycine (Russell 2003). LCA 
can be sulphated at the C-3 position in addition to conjugation with taurine or glycine. 
The presence of a sulphate group prevents intestinal absorption and aids rapid 
elimination of this compound from the body via faeces (Schlmerich 1984). LCA is the 
most cytotoxic bile acid as it consists of one hydroxyl group. CDCA and DCA with 2 
hydroxyl groups are less harmful. CA is less cytotoxic and more hydrophilic as it 
contains 3 hydroxyl groups. UDCA is another naturally occurring bile acid that is  
composed of 2 hydroxyl groups, it is the least cyototoxic bile acid and the most 
hydrophilic bile acid as the hydroxyl group at C7 is in a β conformation rather than an α 
conformation as in CDCA (Figure 1.2 and Table 1.1). In fact, UDCA is used as a 
therapeutic agent in cholestasis. Another type of bile acid that is predominantly 
produced in animals is muricholic acid (MCA).  In rodents, CDCA is converted into 
MCA which is a primary bile acid produced in rodents (Botham & Boyd 1983). 
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   Chenodeoxycholic acid (CDCA)                    Cholic acid (CA)    
 
    
    Lithocholic acid (LCA)         Deoxycholic acid (DCA)  
 
      
Ursodeoxycholic acid (UDCA) 
 
Figure 1. 2: Structure of the most common bile acids. 
Primary bile acids are cholic acid (CA) and chenodeoxycholic acid (CDCA). Secondary 
bile acids are lithocholic acid (LCA) and deoxycholic acid (DCA). Ursodexoycholic 
acid (UDCA) is a therapeutic bile acids.  
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                                                          Hydrophilicity 
 OH group in structure Position of OH group 
 α or β 
UDCA 1 β 
CA 2 α and β 
CDCA 1 α 
DCA 1 α 
 LCA None - 
 
                        Hydrophobicity 
Table 1. 1: Hydrophilicity and hydrophobicity of bile acids. 
Hydrophilicity and hydrophobicity properties of bile acids depend on the presence and 
position of hydroxyl groups (OH) on α/β or α and β.  
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1.3.2 Synthesis of bile acids  
 
The synthesis of bile acids is a complex and highly regulated process. It is regulated by 
the dietary intake of cholesterol. The biosynthesis of bile acids in the liver occurs via 
the classical and alternative pathways which involves the modification of the cholesterol 
ring structure, side chain shortening and conjugation (Russell 2003). Bile acids are 
mainly produced by the classic pathway (Schwarz 1996)(Figure 1.3). CA and CDCA 
are the end products of both pathways. The newly synthesized bile acids are conjugated 
before being transported out of hepatocytes. 
 
The classical pathway, also known as neutral pathway, is initiated by microsomal 
cholesterol 7-α-hydroxylase (CYP7A1). The most important step in the bile acid 
synthesis pathway begins in the liver, where the hydroxylation of cholesterol occurs and 
this step is catalyzed by CYP7A1 (Schwarz 1996, Ishibashi et al. 1996). The catalysis of 
this reaction is also the bile acid synthesis rate limiting step. Transcription factor 
binding sites have been discovered on the CYP7A1 promoter that allow repression and 
activation in response to feedback regulation. In the second step, there is 3β-hydroxy-
C27-steroid-dehydrogenase/isomerise (3β-HSD)-catalyzed conversion of 7α-hydroxy-
cholesterol to 7α-hydroxy-4-cholesten-3-one (Chiang, 2002). Next, cholesterol 12α-
hydroxylase (CYP8B1) converts 7α-hydroxy-4-cholesten-3-one to 7α, 12α-dihydroxy-
4-cholestene-3-one where a hydroxyl group is introduced to the sterol nucleus. Then, 
the aldo-keto reductase family 1 member D1 (AKR1D1) enzyme catalyzes the 
production of 5β-cholestane-3α, 7α-diol and 5β-cholestane-3α, 7α, 12α triol. 
Subsequently, cholesterol 27-α-hydroxylase (CYP27A1) catalyzes the conversion of the 
steroid side chain of 5β-cholestane-3α, 7α-diol and 5β-cholestane-3α, 7α, 12α triol to a 
carboxyl group, which produces CA and CDCA respectively (Figure 1.3). In an 
alternative pathway, also known as the acidic pathway, the first step is initiated by 
CYP27A1 where cholesterol is converted to 27-hydroxycholesterol and 3β-hydroxy-5-
cholestenoic acid. Then these two intermediates are catalyzed by oxysterol 7α-
hydoxylase CYP7B1 to 7α-hydroxysterol intermediates. In the next step there is 3β-
HSD-catalyzed conversion of 7α-hydroxysterol intermediates to 7α-hydroxy-4-
cholesten-3-one. As in the classical pathway, CYP8B1 and AKR1D1 convert 7α-
hydroxy-4-cholesten-3-one to 7α, 12α-dihydroxy-4-cholestene-3-one and 5β-
cholestane-3α intermediates which then lead to production of CA and CDCA 
respectively (Figure 1.3). 
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Figure 1. 3: Schematic overview of bile acid synthesis pathways in the liver. 
 
In the classical pathway the synthesis is initiated by the rate limiting enzyme, CYP7A1. 
In the alternative pathway it is initiated by CYP27A1 and then CYP7B1. Other enzymes 
involved in both pathways are 3β-HSD, CYP8B1 and AKR1D1.  Both pathways 
produce CA and CDCA (Russell, 2003). 
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Bile acids are taken up from the portal vein to hepatocytes through two processes. The 
major uptake process occurs through a sodium-dependent transporter known as Na
+
-
taurocholate cotransporting polypeptide (NTCP), where the influx is driven by 
transmembrane Na
+ 
gradient. NCTP (gene symbol SLC10A1) is predominantly 
expressed in the liver. Bile acid uptake can also occur through Na
+
-independent uptake 
systems which are mediated by members of the Organic anion transporting peptide 
(OATP) family of transporters. Apart from bile acids, OATPs are able to transport other 
compounds such as thyroid hormones, bilirubin conjugates, various drugs and 
xenobiotics. Expression of NTCP and OATP can be altered in pathophysiological 
conditions. When the level of bile acids in the blood is high bile acids themselves 
activate a feedback regulation circuit which involves liver and intestine. This feedback 
regulation is to protect tissues from accumulation of bile acids. The feedback regulation 
is farnesoid X receptor (FXR)-dependent (Figure 1.4). In this pathway, bile acids 
activate FXR and consequently induce the expression of short heterodimer protein 
(SHP). SHP binds to several nuclear receptors, such as liver receptor homologue 1 
(LRH1), which in turn repress the transcriptional activity of CYP7A1 (Goodwin et al. 
2000, Brendel et al. 2002). The other pathway involves FXR and fibroblast growth 
factor- 19 (fgf19). Fgf19 is known as fgf15 in rodents. 
 
Following their synthesis in hepatocytes, bile acids are secreted into the bile canaliculus 
through several members of the ATP- binding cassette (ABC) transporter family. The 
ABC transporters belong to a family of transmembrane transporters which play role in 
the transport of xenobiotics in the gut, liver, brain, kidney and placenta. The P-
glycoprotein (P-gp) is the most studied ABC transporter, encoded by the ABCB1 gene 
which is also known as MDR1(Schinkel 1997). Apart from conjugated bile acid, 
MDR1s main function is to efflux drug into bile canaliculus. The protein encoded by the 
ABCB4 gene, MDR3 (MDR2 in rodents) efflux phosphotidylcholine into the bile 
canaliculus and this is essential for efficient transport of bile acids. MRP2 encoded by 
ABCC2 is responsible for the secretion of xenobiotic and endogenous compounds such 
as bilirubin into bile canaliculus. The bile salt export pump (BSEP) (encoded by the 
ABCB11 gene) transports taurine and glycine-conjugated bile acids across the 
canalicular membrane. Other ABC transporters that are playing roles in the liver are 
MRP3 and MRP4, both transporters are expressed at basolateral membrane of 
hepatocytes. MRP3 and MRP4 are important alternative routes for bile acids and 
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organic ions during bile acid overload under cholestatic condition (Trauner & Boyer 
2003). 
 
 
 
 
Figure 1. 4: Schematic overview of bile acid transporters and FXR-mediated 
feedback inhibitory mechanism of bile acids synthesis and circulation in the liver. 
Bile acids are taken up from portal vein by OATP and mainly by NCTP. Then bile acids 
are excreted by BSEP into bile canaliculus. Bile acids conjugated with taurine or 
glycine are taken up by MRP2 and MDR1. During bile acid overload, basolateral 
membrane transporters (MRP3 and MRP4) mediate efflux of bile acids and organic ions 
into systemic circulation. FXR-α control the enterohepatic circuit and synthesis of  bile 
acids. During bile acid overload under condition of cholestasis, FXR-α is activated and 
subsequently induces SHP expression. Then NTCP and CYP7A1 expression are 
inhibited. The expression of efflux transporters (BSEP, MRP2 and MDR3) are induced 
to increase efflux activity. 
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1.3.3 Bile acids activate signalling pathways 
 
Bile acids are known as regulators of lipid absorption and cholesterol metabolism.  
Recently a new role for bile acids as signalling molecules has been discovered. Bile 
acids have been shown to be involved in various cellular signalling pathways such as 
protein kinase cascades, cyclic AMP (cAMP) synthesis and calcium mobilization 
(Nguyen & Bouscarel 2008). In addition, they have also been shown to regulate 
glucose, cholesterol, triglyceride and energy homeostasis (Thomas et al. 2008). Several 
nuclear hormone receptors, including FXR, have been reported as bile acid ligands. 
FXR-independent bile acid activity has been observed and TGR5, a G-protein-coupled 
receptor (GPCR), has been suggested to play a role. Bile acids have also been studied in 
other GPCR associated pathways, namely muscarinic receptors, epidermal growth 
factor (EGF) and glucagon receptor (Raufman 2003). Of all the receptors known to 
mediate the effects of bile acids FXR and TGR5 are the most studied. 
 
1.3.3.1 The Farnesoid X Receptor  
 
FXR-α is encoded by NR1H4 gene and it is a member of the nuclear hormone receptor 
superfamily which acts in a similar way to other types of nuclear hormone receptor such 
as proliferator activated receptor-γ (PPAR-γ) and liver X receptor α (LXR- α). This 
receptor is activated by a ligand and then acts as transcription factor whose role is to 
regulate expression of certain genes. FXR-α (termed as FXR) may form a dimer with 
RXR when activated by its ligand. There are four isoforms of FXR-α known as α1, α2, 
α3, α4 generated in the human and mouse (Huber et al. 2002, Zhang et al. 2003, Zhang 
et al. 2004). Another member of FXR subfamily of nuclear receptors is FXR-β, also 
known as NR1H5, and this is expressed only in rodents, rabbits and dogs. FXR-β is a 
pseudogene in humans (Otte et al. 2003). FXR is ubiquitously expressed throughout the 
human body with high expression in target organs for bile acids, such as liver and gut. 
Surprisingly, FXR expression is also high in organs which are believed not to be targets 
of bile acids, such as the adrenal glands (Forman et al. 1995, Otte et al. 2003, Bishop-
Bailey et al. 2004). Low levels of FXR mRNA are present in other tissues, including the 
heart, thymus and spleen (Otte et al. 2003, Huber et al. 2002).  
Bile acids regulate their own synthesis and transport through activation of FXR (Figure 
1.4). Bile acids are physiologic ligands for FXR, with CDCA, glycol-CDCA and tauro-
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CDCA being the most potent agonists with EC50 of about 4.5 to 10 µM (Makishima et 
al. 1999, Parks et al. 1999). LCA and DCA are also able to bind to FXR with less 
potency than CDCA. In addition, LCA is a potent ligand for pregnane X receptor (PXR) 
(Staudinger et al. 2001) and vitamin D receptor (VDR) (Makishima et al. 2002). Other 
bile acids such as CA and UDCA are weak activators of FXR. As mentioned before, 
FXR initiates the first pathway of bile acid feedback inhibition in cholesterol 
metabolism in the liver which may be either SHP- dependent or SHP- independent. The 
feedback inhibition pathway functions to repress expression of CYP7A1 (Makishima et 
al. 1999), an enzyme that plays an important role in conversion of cholesterol to bile 
acids.   
 
Bile acids also play a role in lipid metabolism; activation of FXR inhibits conversion of 
cholesterol to bile acids which results in an increase of hepatic and serum levels of LDL 
(Leiss & von Bergmann 1982). In addition, very low density lipoprotein (VLDL) 
production has been reported to correlate with hepatic influx of bile (Angelin 1978, 
Kobayashi 2007). It has been shown that interruption of the enterohepatic circulation, 
which causes a decrease in bile acid influx, leads to induction of VLDL. In line with 
this, FXR knockout mice (FXR
-/-
) show increased triglyceride levels due to an increase 
in VLDL (Sinal et al. 2000). Furthermore, FXR activation by bile acids has been shown 
to induce Apolipoprotein C-II (APOC2), a co-activator of lipoprotein lipase, and lowers 
serum triglycerides (Kanaya et al. 2004).  A few target genes of FXR that are involved 
in lipid metabolism have been identified. Among them is sterol regulatory element-
binding protein 1c (SREBP1c) (Watanabe et al. 2004). SREBP1c is a transcription 
factor that regulates fatty acid and triglyceride homeostasis.  
 
Bile acids have also been reported to play a role in glucose homeostasis. 
Cholestyramine has been shown to improve glycaemic control in patients with type 2 
diabetes (Garg & Grundy 1994). Several papers have shown involvement of FXR in 
mediating the effect of bile acids in glucose homeostasis (Zhang et al. 2006, Cariou et 
al. 2006). In addition, FXR
-/- 
animals
 
have an impairment of glucose tolerance and 
insulin sensitivity (Zhang et al. 2006, Cariou et al. 2006). Moreover, insulin has been 
suggested to inhibit FXR expression (Zhang et al. 2004). Another study showed a 
decrease of FXR expression in animals with diabetes that returned to normal when 
insulin was given (Duran-Sandoval et al. 2005). However, the precise involvement of 
FXR in mediating the effect of bile acids in glucose homeostasis is not clear.  
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FXR is playing many roles in normal and pathological physiology. It has been 
suggested to have interesting therapeutic potential. FXR agonists could protect liver 
from accumulation of toxic bile acids in liver diseases. Moreover, FXR agonists could 
also be used to reduce triglycerides in metabolic diseases such as type 2 diabetes.  
 
1.3.3.2 TGR5 
 
TGR5, also known as membrane-type receptor for bile acids (M-BAR) was recently 
identified as a bile-acid-activated membrane receptor (Maruyama et al. 2002, Kawamata 
et al. 2003). In common with other GPCR, TGR5 selectively couples to GS-protein and 
this subsequently leads to accumulation of cAMP. TGR5 is ubiquitously expressed in 
various tissues with highest expression in the human placenta and spleen (Kawamata et 
al. 2003), whereas moderate expression levels of TGR5 have been demonstrated in 
liver, intestine, brown adipose tissues and lungs (Vassileva et al. 2006, Foord et al. 
2005). Kawamata et al. showed that TGR5 mRNA was abundantly expressed in 
monocytes/macrophages of human and rabbit. TGR5 has been suggested to be 
important for physiological function as its responsiveness to bile acids is highly 
conserved among humans, cows, rabbits, rats and mice (Kawamata et al. 2003).  
 
LCA is the most potent ligand for TGR5 (Kawamata et al. 2003). TGR5 also responds 
to other bile acids, DCA, CDCA, CA and UDCA (Kawamata et al. 2003, Maruyama et 
al. 2002). Although TGR5 is known as receptor for bile acids, the expression of TGR5 
in hepatocytes is not detectable (Fang et al. 2007). However, Maruyama et al. have 
reported the expression of TGR5 at low level in human liver tissue (Maruyama et al. 
2002). This indicates that liver cells other than hepatocytes may express TGR5.  
Recently, Keitel et. al. have demonstrated the expression of TGR5 in liver sinusoidal 
endothelial cells (SECs) (Keitel et al. 2007). SECs form a permeable barrier between 
hepatocytes and blood and therefore TGR5 receptors on the surface of these cells are 
exposed to high concentration of bile acids. In SECs, TGR5 mediated bile acid 
signalling has been shown to occur through cyclic Adenosine Monophosphate (cAMP)-
dependent activation of endothelial nitric oxide synthase (eNOS) (Keitel et al. 2007). 
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Bile acids have also been suggested to be involved in energy homeostasis where they 
are reported to prevent hyperglycaemia and reduce diet-induced obesity in rodents 
(Ikemoto et al. 1997, Watanabe et al. 2006). This involvement appears to be dependent 
upon TGR5 and independent of FXR (Watanabe et al. 2006, Sato et al. 2007). The 
findings have been confirmed with TGR
-/-
 mice, which they have tendency to gain 
weight (Maruyama et al. 2006).  
Recently TGR5 has been reported to have potential role in cell proliferation and 
apoptosis via epidermal growth factor receptor (EGRF) and c-Jun N –terminal kinase 
(JNK) signalling pathway (Yang et al. 2007, Yasuda et al. 2007).  
 
1.3.3.3 Muscarinic receptor 
 
Several studies have demonstrated that bile acids interact with muscarinic receptors 
(Raufman 2003). The first study which indicated the interaction was by Miyata et al 
who showed an inhibiting effect of sodium taurocholate and deoxycholate on serum 
levels of gastrin in rats pre-treated with non-specific muscarinic antagonist atropine 
(Miyata et al. 1995). However the discovery of bile acids as a partial agonist of the 
muscarinic receptor was first proven by Raufman et. al, in the study of the action of 
glycine and taurine conjugates of  bile acids (CA, CDCA, DCA and LCA) on chief cells 
from guinea pig stomach. They demonstrated that taurine conjugated LCA (TLCA) 
inhibits binding of radiolabeled cholinergic ligands ([
3
H]NMS) and causes a significant 
increase in pepsinogen secretion from gastric chief cells (Raufman et al. 1998). The bile 
acid-muscarinic receptor interaction has been further proven in chinese hamster ovary 
(CHO) cells expressing either rat or human muscarinic receptor. It has been shown that 
TLCA interacts with M3 isoform of muscarinic receptors, but not the M1, M2, M4 or M5 
isoforms (Raufman et al. 2002). In addition, interaction of TLCA with the M3 
muscarinic receptor affects the downstream function of the muscarinic receptor,  e.g. 
increase in inositol triphosphate (IP3) and reduced phosphorylation of MAPKs ERK1 
and ERK2 compared to acetylcholine effects (Raufman et al. 2002, Cheng et al. 2002).  
 
The bile acid interaction with muscarinic receptors has also been suggested to play a 
role in cell proliferation. In these studies, administration of bile acids, namely glyco-
conjugated DCA (GDCA), tauro-conjugated DCA (TDCA) and TLCA, stimulated 
proliferation of cells expressing the M3 muscarinic receptor (colon cancer cell lines 
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H508) (Cheng & Raufman 2005). Moreover, this stimulation of H508 proliferation 
effects MAPK phosphorylation through epidermal growth factor receptor (EGFR).  
Recent findings have suggested that tauro-conjugated CA (TCA) activation of glycogen 
synthase and AKT in rat liver occurs through Gαi -coupled GPCR, however the authors 
were unable to show the involvement of M3 muscarinic receptors (Fang et al. 2007). 
 
In another study, it was shown that secondary bile acid deoxycholytaurine stimulates the 
relaxation of phenylephrine-constricted thoracic aortic rings of rat and mice, which have 
been suggested to occur via nitric oxide dependent mechanism. The authors have 
implicated the M3 muscarinic receptor as these effects were reduced in M3 knockout 
mice (Khurana et al. 2005). These effects were also observed in acetylcholine-treated 
tissues.  
 
1.4 Alteration of bile acid regulation in normal and cholestatic pregnancy 
The activity of transporters at the basolateral and canalicular membrane determines the 
secretory function of hepatocytes. The expression of transporter proteins that are 
involved in biliary secretion is regulated at transcriptional and post-transcriptional level 
(Trauner & Boyer 2003). Normal pregnancy affects bile secretory function. In 
experimental rodent models there is a reduction in hepatic transport of organic anions 
(Arrese et al. 2003) and an uptake of bile acids (Ganguly et al. 1994) in the liver of 
pregnant rats. In cholestasis, the normal bile flow is impaired which leads to hepatic and 
systemic accumulation of products usually excreted into bile.  
 
Intrahepatic cholestasis classically occurs in late trimester of pregnancy. Although the 
precise pathogenesis of ICP is still unknown, several mutations or polymorphisms of 
genes encoding for bile transport proteins and nuclear receptors expressed in the liver 
have been reported in ICP. Mutations in genes encoding MDR3 and BSEP have been 
reported in ICP (Painter et al. 2005, Lang et al. 2006, Dixon & Williamson 2008). 
MRP2 mutations are known to cause Dubin-Johnson syndrome (Paulusma et al. 1997). 
In pregnancy, studies have demonstrated a reduction in MRP2 expression in 
experimental animals and estrogen induced cholestasis (Arrese et al. 2003, Trauner et 
al. 1997, Arrese et al. 2008). Recently, polymorphisms in MRP2 were found to be 
associated with ICP (Sookoian et al. 2008).  
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1.5 Bile acid circulation in the fetal compartment 
 
In the adult, elimination routes for endogenous and xenobiotic compounds are mainly 
via the hepatobiliary system and then kidney. However in fetal life, the route for 
elimination of biliary compounds is not well developed. Although bile acids are not 
required for digestion during intrauterine life, the fetal liver is still able to synthesize 
bile acids. In the human fetus, the CDCA and CA are the major components of bile acid 
pool (Nakagawa & Setchell 1990). It has been reported that the fetal bile acid pool also 
contains unusual hydroxyl groups in different positions of the bile acids than are 
normally found in adult (Setchell et al. 1988). Moreover, the fetal bile acid pool also 
contains traces of secondary bile acids such as LCA and DCA which are probably 
transferred from the maternal circulation through the placenta (Monte et al. 1995).  
 
In spite of fetal liver immaturity, the expression of bile acid transporters such as Oatp, 
Bsep and Mrp2 have been demonstrated in rat fetal liver in the late third of gestation 
(Zinchuk et al. 2002, Macias et al. 2006). The efficiency of these transporters at 
elimination of bile acids and endogenous compounds is low.  
 
Bile acid accumulation in fetal serum can lead to severe fetal outcomes such as perinatal 
mortality and stillbirth (Lammert 2003). Most fetal metabolic by-products, including 
bile acids, are transferred to the maternal circulation via the placenta and subsequently 
eliminated by the maternal liver. 
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1.6 Regulation of Cardiac Contraction 
 
The heart is a pump that coordinates contraction of the atria lead to pumping of blood 
from the atria into the ventricles. Ventricles then do most of the hearts work by 
synchronously contracting to pump blood to the rest of the body. The mechanical 
activity of the heart is controlled by a conduction system which lead to coordinated 
depolarization and contraction of the atria and then the ventricles. Whereas cardiac 
impulse initiation and propagation is due to the spontaneous depolarization of sinoatrial 
node cells (DiFrancesco & Robinson 2002). The cardiac function and homeodynamic 
homeostasis are regulated by the autonomic nervous system (ANS); sympathetic 
nervous system (SNS) and parasympathetic nervous system (PSNS) (Olshansky et al. 
2008).  
 
1.6.1 Modulation of contraction by adrenoceptors and muscarinic receptors in 
heart. 
Both systems have an opposing effect on the heart. The SNS is to increase the 
contraction rate of heart, whereas the PSNS has the opposite role. In addition, activation 
of the PSNS can inhibit SNS traffic and vice versa. The interaction between SNS and 
PSNS activities is important to maintain normal cardiac function. These interactions are 
partially modulated by cAMP and cyclic Guanosine Monophosphate (cGMP) as a 
second messenger. Acetylcholine, norepinephrine and epinephrine are the most 
common neurotransmitters released by the ANS. Epinephrine and norepinephrine are 
released from sympathetic nerves that act through adrenergic receptors. Acetylcholine is 
the main neurotransmitter for the PSNS, which bind to two types of cholinergic 
receptor; muscarinic receptors and nicotinic receptors (McCorry 2007).   
 
1.6.1.1 Adrenergic receptors 
 
The adrenergic receptors also known as adrenoceptors(AR) belong to the family of 
seven transmembrane domain G-protein coupled receptors (GPCR). The ARs have been 
showed to mediate positive inotropic and chronotropic effects in cardiac cells (Brodde 
& Michel 1999). Three types of AR have been identified, α1-AR, α2-AR and β-AR. 
Cardiac cells express four subtypes of β-AR: β1-AR β2-AR,  β3-AR and β4-AR 
 37 
 
(Myslivecek 2003). β-iAR activation has been suggested to be a strong stimulus for 
increasing cardiac contraction and heart rate. 
 
Activated adenylyl cyclase (AC) directly binds to the G protein Gs and increases the 
intracellular level of cAMP. Subsequently this leads activation of protein kinase A 
(PKA) and promotes Ca
2+
 influx which enhances contraction (Kaumann 1997) (Figure 
1.3). The downstream targets of β-AR stimulation include ion channels  such as the L-
type Ca
2+
 channel, regulatory proteins and nuclear transcription factors. In addition, 
stimulation of the β-AR may also activate MAPK pathway (Crespo et al. 1995). 
Activation of the AR by isoprenaline in culture has been shown to cause a decrease in 
MR activity (Garofolo et al. 2002, Nomura et al. 1982). 
 
1.6.1.2 Muscarinic receptors 
 
The muscarinic receptor is a G-protein coupled receptor (GPCR) known as the 
muscarinic actetylcholine receptor (mAChR). The mAChRs have been 
pharmacologically characterized into 5 subtypes, M1 to M5 (Caulfield et al. 1993, 
Caulfield & Birdsall 1998)(Table 1.2). Evidence for the heterogeneity of mAChRs was 
strengthened by molecular works such as cloning and sequence analysis (Peralta et al. 
1987, Kubo et al. 1986, Liao et al. 1989). All these subtypes of mAChRs genes have 
been cloned and expressed into various cell lines. Their expression in cell lines has 
generated more information on their potential roles and mechanisms action (Fukuda et 
al. 1988).  
 
The mAChRs are intergral membrane glycoproteins which have seven transmembrane 
domain receptors similar to other members of GPCR. Ligands of muscarinic receptors, 
including acetycholine, interact at the distal N-terminal part of the third transmembrane 
domain of muscarinic receptors (Curtis et al. 1989, Spalding et al. 1994).  
 
The mAChRs are selectively coupled to either Gi/Go or Gq/G11. They are subdivided 
into two groups according to the subunit with which they are coupled. The “odd” 
receptor groups (M1, M3 and M5) couple to Gq/G11 and subsequently stimulate 
phospholipase C. In contrast, the “even” groups (M2 and M4) selectively couple to Gi/Go 
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and subsequently inhibit adenylate cyclase (Trautwein et al. 1982). The stimulation or 
inhibition of adenylate cyclase could leads to variety cellular responses.  
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Table 1. 2:Summary of related muscarinic receptors information                
  
Muscarinic receptors subtypes 
 
 M1 M2 M3 M4 M5 
G-protein 
preference 
Gq/11 Gi/o Gq/11 Gi/o Gq/11 
Second messengers (+ ) PLC, Ca
2+
 /PKC (-) AC (+ ) PLC, Ca
2+
 /PKC (-) AC (+ ) PLC, Ca
2+
 /PKC 
Expression/ 
Location 
Sympathetic ganglia 
Brain, Glands 
 
Heart 
Smooth muscle, Brain 
Gallbladder  
Smooth muscle 
Glands, Brain,  
 
Brain, Striatum 
 
Substantia nigra, striatum 
Antagonist with 
high affinity 
Atropine 
Pirenzepine 
Atropine 
Methoctramine 
 
Atropine 
4-DAMP 
Atropine 
Tripitramine 
Atropine 
Tolterodine 
Functional 
responses 
Involves in inhibition of 
M-current 
Play roles in rate and 
force of contraction in 
heart 
Inhibit Ca
2+
 channels 
 
Play roles in secretion in 
glands 
Inhibit Ca
2+
 channels 
 
Involves in release of 
dopamine in striatum 
Functional effects 
in knockout (KO) 
mice 
Mice showed increase in 
locomotor activity 
(Miyakawa et al. 2001). 
No altered in 
cardiovascular responses 
between KO and wild 
types mouse (Hardouin et 
al. 2002). 
Loss of muscarinic 
agonist-induced 
bradycardia in KO 
mouse(Gomeza et al. 
1999). 
KO mouse show 
discrepancy in working 
memory and behavioural 
flexibility(Seeger et al. 
2004). 
Loss of muscarinic 
agonist-induced 
contraction in smooth 
muscle of stomach, 
unrinary bladder and 
trachea (Stengel et al. 
2002). 
Mice showed significance 
increased in drug-induced 
basal locomotor activity 
(Gomeza et al. 2001). 
Loss of acetylcholine-
mediated dilation in 
arteries and microvessels  
of cerebral (Araya et al. 
2006). 
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The mAChRs are widely expressed throughout the mammalian body (Maeda et al. 
1988). They are known to be involved in diverse physiological and pathophysiological 
functions of the central nervous system and peripheral tissues (Caulfield et al. 1993).  
Their functions have been shown to be determined by subtypes and location. For 
instance, in the central nervous system (CNS), M2 muscarinic receptors may have a role 
in cognitive function and mice defective of M2 muscarinic receptors showed a 
discrepancy in behavioural flexibility and working memory (Tzavara et al. 2003, Seeger 
et al. 2004). In the bladder, M2 muscarinic receptors have been revealed to be indirectly 
involved in mediating bladder contraction (Hedge et al, 1997). In the heart, M2 receptors 
are predominantly expressed (Yang et al. 1993, Maeda et al. 1988, Yang et al. 2002, 
Sharma et al. 1997) and have been shown to be most functionally important in 
modulating cardiac rate and force (Dhein et al. 2001). This is also supported by the 
study of a mice defective for M2 receptors (M2R
-/-
) where binding of radiolabeled 
nonselective muscarinic antagonists [
3
H]quinuiclidinyl benzilate ([
3
H]QNB)] to the 
membrane of the heart were significantly decreased as compared to the wild type. 
Moreover, carbachol-induced bradycardia was not observed in M2R
-/-
 mice (Gomeza et 
al. 1999, Stengel et al. 2000). There is evidence that M2 receptor inhibition of adenylyl 
cyclase subsequently leads to inhibition of voltage-gated calcium channels in the heart 
(Mery et al. 1997)(Figure 1.5). Other subtypes of muscarinic receptors are expressed in 
the heart but their functional roles are not well as known as in other organs (Wang et al. 
2001, Willmy-Matthes et al. 2003).  
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Figure 1. 5: Schematic diagram of β-AR and M2 mACHR regulation. 
 
 In the heart, activatated M2 receptors couple to Gi/Go and subsequently cause inhibition 
of AC and inhibit the increase of intracellular cAMP. These effects lead to a reduction 
in the L-type Ca
2+
 current and force of contraction (Belardinelli & Isenberg 1983, Mery 
et al. 1997). In addition, acetylcholine induces an increase in intracellular cGMP levels 
and stimulates production of constitutive endothelial nitric oxide synthase (NOS3) 
(Kelly 1996).   
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1.6.2 Excitation-contraction (EC) coupling 
 
Excitation-contraction (EC) coupling is essential to the function of cardiomyocytes. The 
cellular properties which are fundamental for the regulation of EC undergo vital 
changes as the heart develops. In mature cardiac myocytes, during phase 2 of an action 
potential (AP) Ca
2+ 
enters via depolarization-activated L-type Ca
2+ 
channel and 
contributes to the plateau of the AP. This influx of Ca
2+ 
leads to the contraction of cells 
from the resting diastolic state. Moreover, this initial influx of Ca
2+ 
signal stimulates the 
release of Ca
2+ 
from intracellular stores (sarcoplasmic reticulum), a process known as 
Ca
2+ 
- induced Ca
2+ 
release (CICR) mechanism (Bers 2002). The role of the 
sarcoplasmic reticulum (SR) in contraction is characterised by the expression of 
proteins such as ryanodine receptor (RyR), phospholamban and SR Ca
2+ 
ATPase 2a 
(SERCA2a). 
 
The involvement of the SR in Ca
2+ 
release to EC coupling in fetal cardiac cells is low 
compared to adult. It is known the SR during fetal life is not well developed (Nakanishi 
et al. 1988). Fetal cardiac cells have been suggested to be more dependent on 
transarcolemmal Ca
2+ 
influx for generation of contraction than Ca
2+ 
release from SR 
(Itzhaki et al. 2006). However, some studies have shown mRNA and proteins of SR 
SERCA2a and RyR2 are already detected in the immature beating cardiomyocytes 
(Moorman et al. 1995, Moorman et al. 2000).  
 
 
1.6.2.1    Calcium induced cardiac arrhythmia 
 
Arrhythmia is a rhythm disturbance of the heart that originates from abnormalities in 
impulse formation and propagation. In general, arrhythmogenesis is frequently 
associated with modulation of the heart rate which may increase (tachycardia) or 
decrease (bradycardia). Tachycardia or tachyarrhythmias cause a rapid heartbeat, and 
hence blood pressure cannot be sustained and that could lead to a sudden death. 
Similarly, bradycardia or „bradyarrhythmias‟ could also lead to death (Keating & 
Sanguinetti 2001). Tachycardia could also be the result of abnormal impulses in the 
normal cardiac cycle which is caused by mechanisms such as reentry, triggered activity 
and automaticity. The most severe tachyarrhtythmias are ventricular tachycardia, 
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ventricular fibrillation and torsades de pointes ventricular tachycardia (Keating & 
Sanguinetti 2001).   
Mechanism of arrhtyhmias has been studied on isolated cardiac tissue and it has been 
shown that arrhtyhmia is a result of either focal or non-focal mechanism. Focal 
mechanisms may result from abnormal impulse initiation (automaticity) and either 
delayed or early afterdepolarizations, whereasnon-focal mechanisms can be caused by 
various type of re-entry (Rosen 1988).  
Regulation of the calcium cycle is critical for normal cardiac function. The 
myofilaments shorten and elongate cyclically in response to the cyclic manner in which 
the calcium concentration rises and membrane depolarization occurs. In adequate 
calcium delivery to myofilaments leads to a reduction in contraction, while calcium 
overload contributes to other pathological effects on membrane currents and 
subsequently leads to cell death (Wang & Goldhaber 2004). It is well known that Ca
2+ 
overload in the sacroplasmic reticulum (SR) contributes to arrhythmia (Klein 1999, 
Cheng et al. 1996).  
 
 
1.7 Bile acids cause abnormal contraction and calcium dynamics 
 
In isolated rat hepatocytes, bile acids cause an increase in cytosolic calcium level which 
is similar to one seen in the presence of other agonists (Anwer et al. 1988).  Several 
studies have proposed that taurine conjugates of LCA cause the release of intracellular 
calcium from inositol phosphate (IP3)-sensitive stores by permeabilization of the 
endoplasmic reticulum (Combettes et al. 1988, Combettes et al. 1989, Combettes et al. 
1988). In vascular endothelial cells, DCA, CDCA and taurine conjugates have been 
shown to increase in intracellular calcium mobilisation from IP3- sensitive stores. 
However, this is not seen in all cell types, for example it was not observed in human 
platelets or neuroblastoma cell lines (NG108-15) (Coquil et al. 1991). This effect of bile 
acids on calcium has therefore been suggested to be cell specific. 
  
However the effect of bile acid on intracellular calcium in cardiac cells is not well 
established. A previous study has demonstrated that a primary bile acid TC alters the 
rate and rhythm of cardiomyocytes contraction and simultaneously causes abnormal 
Ca
2+
 dynamics in neonatal rat cardiomyocytes (Williamson et al. 2001). Addition of TC 
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to neonatal rat cardiomyocyte cultures reduced the amplitude of contraction as well as 
causing dysrhythmias. Furthermore the arrhythmogenic effect was different in 
individual cells and TC caused desynchronization of Ca
2+
 dynamics (Gorelik et al. 
2002, Williamson et al. 2001). Recently, TC has been shown to cause abnormal Ca
2+
 
dynamics in early but not late stages of development of mouse embryonic stem cell-
derived cardiomyocytes (Sheikh Abdul Kadir et al. 2009). 
1.8 Models to study bile acid-induced arrhythmia 
 
As it is not possible to perform controlled clinical trials of the effects drugs or 
metabolites that are raised in maternal diseases such as ICP on fetal outcome, in vitro 
models such as cell culture remain an important source of knowledge about the effects 
of these agents. Primary culture of neonatal rat cardiomyocytes is a well-established 
model that allows the study of biochemical, morphological and electrophysiological 
characteristics of the heart. This model is extensively used to study heart disease such as 
myocardial ischaemia and to study transport and toxicity of drugs (Estevez et al. 2000). 
Another recently developed heart model is embryonic stem cell (ESC)-derived 
cardiomyocytes, a potential tool to also study and understand mechanisms underlying 
the transition from the embryonic to the adult phenotype (Boheler et al. 2002). 
 
1.8.1 Neonatal Rat Cardiomyocytes (NRCM) as a heart model  
The neonatal rat cardiomyocyte (NRCM) culture is a well-established model for 
studying drug transport, toxicity and the cardioprotective effects of drugs (Estevez et al. 
2000, Kleiner et al. 2008). This model allows the testing of potential therapeutic 
compounds. Indeed cardiomyocytes can also be obtained from adult rats, however 
primary adult cardiomyocytes do not resemble fetal cells. In that sense NRCM are more 
suitable as a model of the fetal phenotype, as they are immature and lack the structured 
morphology of adult cells.  
 
Apart from the rat, viable cardiomyocytes can be isolated from other species including 
rabbit (Delbridge et al. 1996), ferret (Boyett et al. 1988), sheep (Kim 2002), pig (Louch 
et al. 2004), frog (Fischmeister & Shrier 1989), mouse (Gong et al. 2002) and guinea 
pig (Belevych et al. 2001). At present, the isolation of cardiomyocytes from rats has 
been extensively used. Significantly, cardiomyocytes have also been prepared from 
human atrial and ventricular tissues (Harding et al. 1990, Houser et al. 2000). 
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1.8.2 Embryonic stem cell-derived cardiomyocytes (ESCM) 
ESCs are undifferentiated and pluripotent cells derived from inner cell mass of 
blastocyst stage embryos (Thomson et al. 1998)(Figure 1.6). The pluripotent ESCs have 
two basics properties: firstly, they are able to grow endlessly in an undifferentiated state 
and secondly, they have the potential to differentiate into many specialized cell types. 
The ESCs can be grown in an undifferentiated state ad infinitum in culture without 
losing their genetic and epigenetic properties. ESCs are different from other types of 
stem cells as they can generate all three germ layers: mesoderm, ectoderm and 
endoderm (Itskovitz-Eldor et al. 2000). The protocol for ESCs differentiation into more 
specialized cell types has been established for mouse cells. That includes 
cardiomyocytes (Hescheler et al. 1997), neurons and hepatocytes (Wobus & Boheler 
2005).  The differentiation protocols are well established for both human and mouse 
(Mummery et al. 2002). This unique capability of ESCs has made them an important 
new tool to use in basic research.  
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Figure 1. 6: Embryonic stem cells (ESC) are derived from inner cellular mass.  
The blastocyst is formed from the morula.  Both human and mouse ESCs are derived 
from in vitro cultured cells of the inner cellular mass (ICM) which have the capability to 
differentiate into all somatic cells lineages. Cells from each primary germ layers have 
capacity to differentiate into a specialized cell types such as neuron, epithelial cells, 
cardiomyocytes, hepatocytes and pancreas  (Wobus & Boheler 2005). 
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1.8.2.1 Mouse embryonic stem cell-derived cardiomyocytes (mESCM) 
 
Mouse ESCs (mESC) are grown either on feeder layers of non-proliferating fibroblasts 
or in the presence of conditioned medium from these fibroblasts.  Leukemia inhibitory 
factor (LIF) is added to the medium to prevent spontaneous differentiation. The mESC 
start to differentiate, when the cells are withdrawn from feeder layer and LIF. The initial 
step in ES cell differentiation in culture is an aggregation step where structures called 
embryoid bodies (EBs) form.  The EBs then differentiate into specialized cell types, 
including cardiomyocytes. The differentiation of EBs is determined by several factors, 
namely initial number of cells in EBs, media used, growth factors added and time of EB 
incubation (Wobus & Boheler 2005). During differentiation of EBs, cardiomyocytes are 
formed between a superficial epithelial layer and a basal layer of mesenchymal cells 
inside the developing EBs. Cardiomyocytes are easily identified as they start beating 
spontaneously after 2 to 4 days of plating. As the differentiation continues, the 
cardiomyocyte rate of contraction increases, however as they reach maturation the rate 
of contraction decreases in line with normal mouse heart development (Boheler et al. 
2002).  
 
The differentiation of cardiomyocytes in culture can be divided into 3 stages known as 
early, intermediate and terminal stages (Wobus & Boheler 2005). During the early stage 
the culture consists of pacemaker-like or primary myocardial-like cells, whereas at the 
terminal stage the culture consists of atrial-like cells, ventricular-like cells, nodal-like 
cells, His-like cells and Purkinje-like cells (Wobus & Boheler 2005). At the early stage 
of differentiation, cardiomyocytes contain different degrees of myofibril organization. 
Some myofibrils are sparse and unorganized, others show indication of A and I bands 
(Westfall et al. 1997). As cardiomyocytes continue to differentiate, cells become 
elongated with sarcomeres and myofibrils that are well-developed. Consistent with the 
developing heart, the mononucleated and rod shaped contracting ESCM develop cell-
cell junctions (Westfall et al. 1997). During the terminal stage of differentiation, densely 
packed myofibrils show well organized architecture and sarcomeres obtain well defined 
A bands, I bands and Z disks (Westfall et al. 1997, Fassler et al. 1996). 
 
Cardiac-associated genes are expressed during differentiation of ESCM and the 
appearance of gene products is controlled in the same manner as seen in cardiomyocytes 
during heart development in vivo.  During early ESCM differentiation, GATA-4 and 
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NKx2.5 are expressed in EBs and then followed by α-myosin heavy chain (α-MHC), β-
myosin heavy chain (β-MHC), myosin light chain (MLC)-2v and phospholamban 
(Westfall et al. 1997). Sarcomeric proteins appear in ESCM in the same order as when 
differentiation in vivo occurs, first titin (Z disk), then α-actinin, myomesin, titin (M 
band), and finally MHC, α-actin, cardiac troponin T and M protein (Boheler et al. 
2002). At the terminal stage of differentiation mESCM become responsive to β-AR 
stimulation (Maltsev et al. 1999). Similar to NRCM, mESCM are also responsive to the 
effect of a pro-arrhythmic drug doxorubicin and this effect can be inhibited by esmolol 
(Gorelik et al. 2006). 
 
Differentiation of mouse ESCs into cardiomyocytes permits studies of genes important 
for cardiac development (Boheler et al. 2002). Numerous studies have used the insertion 
of certain cardiac markers by genetic manipulation to ensure that pure cell populations 
of cardiac lineages are selected for transplantation.  The α-MHC promoter (Klug 1996) 
and MLC-2v promoter coupled with GFP (Meyer et al. 2000) have been inserted into 
mouse ESCs for selection. Recently, mESCM have been produced on a large scale by 
genetic selection and by growing them in a bioreactor (Zandstra 2003). This model has 
led to novel insights into the functional role of signalling molecules such as 
transcription factors and calcium regulators. In addition, the interaction between 
contractile proteins and the extracellular matrix (ECM) has been uncovered in in vivo 
heart development (Narita et. al, 1997; Ding et. al, 1999 ECM; Yang et. al 2002).  
 
1.8.2.2 Human embryonic stem cell-derived cardiomyocyes (hESCM) 
Cardiomyocytyes derived from human ESC (hESC) were first reported by Kehat et. al 
using the human ES cell line H9 (Kehat et al. 2001). Several cell lines of hESCM have 
been developed and used for experiments by many groups of researchers, including H1, 
H7, H9.1, H9.2 and H14 cell lines. Each cell line appears to have different percentage of 
beating EBs after differentiation (Xu et al. 2002, He et al. 2003, He et al. 2003). This 
deviation may be due to genetic history of the individual ICM used to derive ESCs. 
Alternatively, different approaches in derivation and cultivation of ES cells and 
differentiating them into EBs may account for the discrepancy (Allegrucci 2007).  
 
The way of culturing undifferentiated ES cells often determines the number of cells 
obtained and stability of differentiation in both mouse and human ESCM. In mESCM 
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the growth factor LIF is the main agent that aids in preventing spontaneous 
differentiation, whereas in hESCM the growth factor used for that purpose is basic 
fibroblast growth factor (bFGF) (Boheler et al. 2002) (Xu et. al, 2005).  In hESCs either 
a mouse fibroblast feeder layer or conditioned medium have been used as additional 
factors that keep ES cells in an undifferentiated state (Harding et al. 2007). However, 
recently hESC have been derived and grown in without any animal-derived supplements 
and conditions (Xu et. al, 2005; Klimanskaya et. al, 2005). Similar to mESC, 
withdrawal of bFGF allowes cells to differentiate into larger aggregates (EB). In hESC 
single cells can be obtained by mechanical or enzymatic methods, although this is not as 
well established as in mESC (Yoon et. al, 2006). Subsequently, the developed EB are 
transferred into suspension culture for 3 to 5 days before being plated. Mummery et. al 
have shown a different approach to obtain hESCM by co-culturing hESC with a mouse 
visceral endoderm-like cell line (END-2) (Mummery et al. 2002). This approach has 
resulted in cultures with more beating areas than in the conventional method, 
approximately 35% of beating areas after 12 days of differentiation in co-culture. In 
addition, Xu et. al have demonstrated by using END-2-conditioned medium that the 
differentiation of cardiomyocytes from hESCs can be further enhanced (Xu et. al , 
2008). 
 
Cardiomyocytes begin to develop as early as 4 days after plating (Kehat et al. 2001). 
After 12 to 20 days of differentiation, cardiomyocytes are generally detected by their 
main characteristic; i.e. spontaneous contraction (Kehat et al. 2001). Moreover, they can 
be identified by their markers such as cardiac MHC, MLCv, GATA-4 and actin (Wei et 
al. 2005). The cardiac-specific markers appear normally at day 4 to 14 after induction of 
differentiation. At an early stage of differentiation hESCMs consist of unorganised 
myofibrils and mononucleated cells which resemble early fetal cardiomyocytes (Snir et 
al. 2003). After 60 days of differentiation, myofibrils become organised and sarcomeres 
appear with clearly defined Z-lines and A and I bands that resemble the adult heart 
phenotype (Snir et al. 2003).  
 
Cardiomyocytes derived from hESCs have been demonstrated to respond to the α1-AR 
agonist, phenylephrine, and β1-AR agonist, isoprenaline, as observed normally in fetal 
cardiomyocytes (Kehat et al. 2001)(Denning et. al, 2006)(Pal and Khanna 2007). 
Muscarinic receptor induction has also been reported in the early stage of differentiation 
(Harding et al. 2007), however it has not been studied in detail.  
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HESCMs have been suggested as the best candidates for the cell replacement therapy 
for cardiovascular diseases where the injured cardiomyocytes could be replaced by 
healthy cardiomyocytes (Pal and Khanna 2007).  However, there are still several 
obstacles that need to be tackled before hESCM can be applied clinically. The major 
obstacle is to find a differentiation approach, which could yield a homogenous 
population of cardiomyocytes, as the highest percentage of beating area obtained 
currently does not exceed 40% (Harding et. al, 2007). Therefore, further investigations 
and clinical trials need to be done before hESCM can be accepted as a treatment for 
cardiovascular diseases such as myocardial infarction. 
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1.9 Hypothesis and aims 
 
Hypothesis 
1. Fetal cardiac cells are more susceptible to the effect of bile acids. 
2. Bile acid-induced arrhythmia in the cardiac cells is mediated by the key bile 
acid transporters and nuclear receptor. 
3. Bile acids-induced arrhythmia in the cardiac cells is mediated by muscarinic 
receptors. 
Aims 
The aim of this project is to use in vitro models to investigate the mechanisms 
underlying the effects of bile acids on fetal heart. Specifically this project aimed to 
establish whether:- 
1. There are differences in susceptibility to the arrhythmogenic effect of 
the bile acid taurocholate (TC) with maturation of cardiomyocytes in 
culture. 
2. TC influences gene expression in cardiomyocytes by expressing key bile 
acid transporter and nuclear receptors found in the „classical‟ bile acid 
pathway. 
3. The muscarinic receptor is involved in bile acid-induced dysrhythmia in 
cardiomyocytes. 
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Materials and Methods 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemical, Reagents and Solvents 
 
Absolute Ethanol                    Fisher Scientific 
30% Acrylamide/Bis Solution                          Bio-Rad 
Agarose powder                            Roche 
Ammonium Persulphate (APS)                          Bio-Rad 
Atropine       Sigma 
Bovine Serum Albumin (BSA)                          Sigma 
Calcium chloride                            Sigma 
Carbamylcholine (Carbachol)     Sigma 
4-DAMP mustard hydrochloride    Sigma 
DEPC-treated H2O      Ambion 
Dimethyl sulfoxide (DMSO)     Sigma 
Ethylenediaminetetraacetic acid (EDTA)         Sigma  
Fluo-4 AM       Invitrogen 
Formaldehyde       Sigma 
Glucose       Sigma 
Glycerol       BDH 
Glycine       Sigma 
GW4064       Sigma 
Hydrochloric acid      BDH 
Isopropanol       Sigma 
Magnesium Chloride      Sigma 
Magnesium Sulfate      BDH 
Methanol       BDH 
Methoctramine      Sigma 
NG-monomethyl-L-Arginine     Sigma 
N,N,N‟.N‟-Tetramethylethylenediamine (TEMED)  Sigma   
N-(2-Hydroxethyl)piperazine-N‟-(2-ethanesulfonic  Sigma 
    acid) (HEPES)  
Pertussis Toxin      Sigma 
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Pirenzepine dihydrochloride     Sigma  
Potassium Phosphate dibasic     Sigma 
Sodium Chloride      BDH 
Sodium Deoxycholate     Sigma 
Sodium Dodecyl Sulphate (SDS)    BDH 
Sodium Fluoride      Sigma 
Sodium Hydroxide      BDH 
Sodium Taurocholate      Sigma  
Tris Base       BDH 
Triton X-100       Sigma 
Tween 20       BDH 
Ursodeoxycholic acid      Sigma 
β-mercaptoethanol      Sigma 
 
2.1.2 Radiochemicals 
 
[
3
H]-taurocholic acid ([
3
H]-TC)    Perkin Elmer 
[
3
H]-N-methylscopolamine ([
3
H]-NMS)   Amersham Biosciences 
 
2.1.3 Cell lines 
Huh7, human hepatoma cells 
HEK293T, human embryonic kidney cells 
CHO, chinese hamster ovary cells 
CHO-M2, chinese hamster ovary cells expressing M2 muscarinic receptor, a kind gift 
from Prof. Andrew Tobin, Leicester University, UK 
hESCM line H7, Human Embryonic stem cells-derived cardiomyocytes, supplied by 
Geron Corporation (Menlo Park, CA) 
mESCM line D3, Mouse Embryonic stem cells-derived cardiomyocytes 
2.1.4 Enzymes 
Collagenase (Collagenase Type II CLS2)   Worthington Biochemical 
1X Pancreatin       Sigma 
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2.1.5 Kits 
RNeasy Mini Kit  (74104)     Qiagen 
RNase-Free DNase set (79254)    Qiagen 
Advantage RT-for-PCR Kit (639505)   Clontech Laboratories 
BCA Protein Assay Kit     Pierce 
ECL plus Western Blotting     GE Healthcare 
    Detection Reagents 
 
2.1.6 siRNA 
All siRNA reagents were purchased from Thermo Scientific Dharmacon. 
siCONTROL Non-targeting siRNA Pool (D-001210) 
siGENOME SMARTpool siRNA targeted to the rat CHRM2 (M-092972) 
 
2.1.7 Antibodies 
Primary 
FXR        R&D Systems 
β-actin        Abcam 
α-actinin       Santa Cruz Biotechnology 
 
Secondary 
Alexa Fluor 488 goat anti-mouse IgG   Invitrogen 
Horseradish peroxidase (HRP)-conjugated   Dako 
   Goat anti-rabbit IgG 
HRP-conjugated goat anti-mouse IgG   Santa Cruz Biotechnology 
 
 
2.1.8 Cell culture Media and Materials 
 
Dulbecco‟s Modified Eagles Medium (DMEM)  Invitrogen  
      containing 4.5g/L glucose and 25Mm HEPES 
DMEM        Invitrogen 
      without L-glutamine and phenol red 
199 medium        Invitrogen 
  56 
     containing 25Mm HEPES 
Knockout (KO) DMEM     Invitrogen 
     Containing 4.5g/L glucose  
KO serum replacement     Invitrogen 
Horse serum, heat inactivated     Sigma 
Foetal Bovine serum, heat inactivated    Sigma 
Foetal bovine serum (Charcoal/dextran)   Fisher Scientific 
Gelatin       Sigma 
Glass coverslips 10 mm     VWR 
Glass coverslips 13 mm     VWR 
L-Glutamine, 200mM (100X)    Invitrogen   
L15 medium       Invitrogen 
Leukaemia inhibitory factor (LIF)    Chemicon 
Non-essential amino acids (100X)    Invitrogen 
Opti-MEM reduced serum media (1X)   Invitrogen 
Penicillin(10000U/ml) – Streptomycin(10000µg/ml) Invitrogen 
     Solution (100X) 
Basic Fibroblast Growth Factor (bFGF)   Invitrogen 
Trypsin-EDTA Solution (1X)     Sigma 
Tissue culture plasticware  Corning, Orange Scientific, 
Fisher Scientific 
   
2.1.9 Buffer, Solutions and Gels 
All chemicals were obtained from Sigma Poole UK unless otherwise stated. All buffers 
and solution were made with deionised water. 
  
ADS buffer 
34 mM NaCl 
23.8 mM HEPES 
6 mM NaH2PO4 
5 mM Glucose 
1 mM KCl 
0.5 mM MgSO4 
Adjusted to pH 7.35 with NaOH 
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FRET buffer 
144 mM NaCl 
5 mM KCl 
2 mM CaCl2 
1 mM MgCl2 
10 mM HEPES 
Adjusted to pH 7.3 with NaOH 
 
Phosphate Buffered Saline (PBS) 
140 mM NaCl 
2.5 mM KCl 
1.5 mM KH2PO4 , pH 7.2 
10 mM Na2HPO4, pH 7.2 
Adjusted to pH 7.4 with HCL 
 
Tris Buffered Saline (TBS) 
130 mM NaCl 
20 mM Tris, pH 7.6 
Adjusted to pH 7.4 with HCL 
 
TBS-Tween 20 (TBS-T) 
0.1% Tween 20 in TBS 
 
RadioImmuno Precipitation Assay (RIPA) Buffer 
1% NP-40 (v/v) 
1% Triton-100 (v/v) 
150 mM NaCl 
5 mM EDTA 
1% Sodium Deoxycholate (w/v) 
0.1% SDS (w/v) 
10 mM Tris, pH 7.2 
1 tablet of Complete Protease Inhibitor Cocktail (Roche Diagnostic) per 50 ml of buffer 
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SDS Polyacrylamide gel electrophoresis 
Western SDS-PAGE Resolving gel 
150 mM Trizma-Base pH 8.8 
1% (w/v) sodium dodecyl sulphate (SDS) 
10% (v/v) Acrylamide Bis Solution (29:1) 
0.1% (w/v) ammonium persulfate 
0.001% (v/v) TEMED 
 
Western SDS-PAGE Stacking gel 
500 mM Trizma-Base pH 6.8 
1% (w/v) SDS 
30% (v/v) Acrylamide Bis solution (29:1) 
0.1% (w/v) ammonium persulfate 
0.01% (v/v) TEMED 
 
Western SDS Running Buffer (10x) 
250 mM Tris-Base 
1.9 M Glycine 
1% SDS (w/v)  
 
Western SDS Transfer Buffer 
25 mM Tris-Base 
192 mM Glycine 
20%  (v/v) Methanol 
 
Western Blocking Buffer solution 
For Phosphorylated Protein: 5% (w/v) non-fat milk in TBS-T 
Others: 5% (w/v) non-fat milk in PBS-Tween 
 
Western Antibody incubation solution 
For Phosphorylated Protein: 3% (w/v) BSA in TBS-T 
Others: PBS-Tween 
2.1.10 Miscellaneous 
Diethylpyrocarbonate (DEPC) treated water   Ambion 
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ECL hyperfilm      Amersham 
Fluo-4 AM (Acetoxymethyl)     Invitrogen 
Lane Marker Sample Buffers for protein   Thermo Scientific 
Milk Powder       Sigma 
Nitrocellulose Membrane     Amersham 
Optically Clear Adhesive Seal Sheets   Abgene 
Origin software       OriginLab Corporation 
Primers       Invitrogen  
RNaseZap       Ambion 
See Blue Plus2 Prestained     Invitrogen 
       Protein Markers 
2x Jump-start SYBR Green Taq ReadyMix   Sigma 
Vectashield Mounting Media     Vector Laboratories 
       With DAPI (4‟,6 diamidino-2-phenylindole) 
Ultima Gold Scintillation cocktail    Perkin Elmer 
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2.2 Cell Culture and Experimental Models 
All cell culture work has been performed by myself except for embryonic stem cell-
derived cardiomyocytes, this work has been done with the kind assistance of Dr. Nadire 
Ali. 
In this study the three types of cells; neonatal rat cardiomyocytes, mouse embryonic 
stem cell-derived cardiomyocytes and human embryonic stem cell-derived 
cardiomyocytes were mainly used as an in vitro models. Experimental evidence related 
to possible mechanisms of fetal death in ICP is scarce partly because of the difficulties 
and ethical issues related to its direct study in vivo. The use of cultured cells offers an 
alternative to in vivo studies. Procurement of human fetal heart cells is difficult as 
ideally cells from relatively late termination of pregnancy (i.e. after 14 weeks‟ 
gestation) should be used as these are more likely to contract spontaneously. However 
termination is rare at this gestation and only a minority of women will consent to the 
use of the fetal tissues. Therefore, there is an urgent need for the development of 
alternative sources of fetal-like cells. Recently it has been shown that embryonic stem 
cells can be turned into more differentiated cells, including cardiomyocytes. 
 
2.2.1 Maintenance of Huh7, CHO and CHO expressing M2 muscarinic receptor 
Cells were routinely grown in 75 cm
2 
tissue culture flasks at 37
o
C in a humid 
atmosphere with 5% (v/v) carbon dioxide (CO2). Cells were maintained in DMEM 
supplemented with 10% (v/v) FCS, 1% (v/v) penicillin/streptomyocin and 1% (v/v) L-
glutamine. Cell cultures were passaged when they reached 70% to 80% confluence. 
Briefly, the medium was removed and cells were washed with 10 ml of pre-warmed 
PBS. The cells were then incubated with 1 ml of pre-warmed trypsin-EDTA at 37
o
C for 
1 to 3 minutes and gently tapped to dislodge cells. The activity of trypsin was stopped 
by addition of 10 ml of pre-warmed DMEM supplemented with FCS. The cell 
suspension was centrifuged at 1000 RPM for 5 minutes. The cell pellet was resuspended 
in pre-warmed DMEM supplemented with FCS, penicillin/streptomycin and L-
glutamine. Cells were seeded in 12 well-plates and coverslips for experiment. Otherwise 
the cells were seeded in 75 cm
2 
tissue culture flasks for maintenance.  
For cells stock storage, the cell pellet as obtained above was resuspended in 1 ml of 
phenol red free DMEM containing 10% FCS and 10% DMSO.  The suspension was 
transferred to 1.5 ml cryogenic vials and placed in an isopropyl alcohol-filled freezing 
container at – 80 oC. 
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2.2.2 Primary neonatal rat Cardiomyocytes (NRCM)  
The technique of isolating and culturing neonatal cardiomyocytes was first established 
in 1960. It has been shown that the cultured cardiomyocytes beat spontaneously and 
eventually form synchronously beating clusters. Neonatal ventricular myocytes were 
isolated from the hearts of 1-2 day old Sprague-Dawley rats. The newborn rats were 
culled by decapitation and the hearts were excised. The hearts were washed in ADS 
buffer to remove blood, and the atrial part was removed. The ventricles were minced 
and incubated with the enzyme solution of pancreatin and collagenase for 5 minutes. 
Then the minced hearts were incubated again with the enzyme solution. After 
incubation with enzyme solution, fetal calf serum was added to stop enzyme proteolytic 
activity and the mixture was centrifuged at 1000rpm for 5 minutes. The cell pellet was 
suspended in fresh fetal calf serum and cell suspension was kept in a 37
o
C incubator 
with 5% CO
2
. The minced hearts were incubated again in a fresh enzyme solution and 
the digestion steps were repeated four times (Table 2.1). Suspensions of cells were 
pooled together and centrifuged at 1000rpm for 5 minutes. The sediment of cells was re-
suspended in plating media which consists of DMEM medium with 20% Medium 199 
(v/v), 10% horse serum(v/v), 5% foetal calf serum (v/v), 200 μg/ml streptomycin, 
200U/ml penicillin. The cells were plated on 60mm culture dishes for 45 minutes to 
eliminate non-muscle cells, e.g. fibroblasts, as they attach to the culture dish faster than 
CM, this is called the “pre-plating step”(Estevez et al. 2000). After 45 minutes non 
attached cells were collected, and cultured on glass coverslips or 12-well plates to the 
required density. Cells were used on the following 2-3 days when a small network of 
cardiomyocytes formed.  
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Digestion step 1 2 3 4 5 
Volume of Enzyme 10 ml  8 ml  8 ml  6 ml  6 ml  
Time of incubation 
(min) 
20  25  25  15  20  
Speed of shaking 
incubator 
7.5 6.5 6.5 6.5/7.5 6.5 
Collection #1      #2 #3 #4 #5 
 
Table 2. 1: Summarizing the digestion step in primary neonatal rat cardiomyocyte 
isolation. 
 
 
2.2.3 Embryonic Stem Cell-derived Cardiomyocytes 
ES cells are derived from the inner cell mass of the blastocyst and are able to 
differentiate in vitro into a variety of cell types including cardiomyocytes (Boheler et. 
al., 2002).  The differentiation of mouse and human ES cells into cardiomyocytes is 
well established (Mummery et. al, 2002). 
 
2.2.3.1 Mouse Embryonic Stem Cell –derived Cardiomyocytes (D3 line) 
The ES cells of the mouse line D3 were proliferated on a confluent layer of mitomycin 
C treated, mitotically inactive SNL feeder fibroblasts (iSNL) in (4.5g/L) glucose 
Dulbecco‟s modified Eagle's medium (KO-DMEM), supplemented with 15% Knockout 
serum replacement (KOSR), 2mM L-glutamax, 1% non-essential amino acids (100X 
stock), 50U/mL penicillin, 50µg/mL streptomycin, 0.1mM -mercaptoethanol (Sigma), 
and 500U/mL leukaemia inhibitory factor (LIF; ESGRO-LIF, Chemicon, Harrow, UK). 
In order to induce differentiation, the feeder cells were removed from the cultures either 
by attachment of fibroblasts onto plastic during 1 hour of incubation in the presence of 
1000 U/mL LIF, or culturing of cells for at least two passages on gelatinised flasks 
under non-feeder cell dependent conditions, with 1000U/mL of LIF in the culture 
medium (Figure 2.1).  After day 1 of differentiation, the cells were cultivated into 
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embryoid bodies (EBs) in hanging drops, by culturing 400 cells in each drop of 20µl of 
differentiation medium, which consisted of high (4.5g/L) glucose DMEM, 
supplemented with 15% FCS (batch-tested for optimum cardiomyocyte differentiation), 
2mM L-glutamax, 1% non-essential amino acids (100X stock), 100U/mL penicillin, 
100µg/mL streptomycin, 0.1mM -mercaptoethanol, and without LIF. Following 2 days 
of differentiation, EBs formed, were flooded with 10mL of the same medium and were 
grown for a further 5 day period in suspension culture (50-60 EBs/10-cm Petri dish). 
Subsequently, 1-2 EBs were plated out onto 0.1% gelatin-coated 10 mm glass 
coverslips at day 7 of differentiationin 1 mL of medium in each well of a 24-well-plate 
(Nunc); after 2 days, the volume of medium was increased to 2 mL.  The beating cells 
of ESCM typically appeared at around Day 8 onwards.  
 
 
 
 
Figure 2. 1: Schematic diagram of induction of the D3 murine Embryonic stem 
cells differentiation. 
 
2.2.3.2 Human Embryonic Stem Cell-derived Cardiomyocytes (H7 line) 
The ES cells of H7 line were purchased from Geron Corporation (in collaboration with 
Prof S. Harding). Propagation of human ES cells using the same method as mouse ES 
Undifferentiated mES cells (D3) 
Hanging drop 
Formation of embryoid bodies (EB) 
3-5 days suspension culture 
Plating EB 
Adherent culture on glass coverslips 
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cells but the LIF and SNL feeder were replaced with bFGF and mouse embryonic 
fibroblast (MEF) feeder.  
 
Maintenance, propagation and differentiation of human H7 ES cells 
Human ESCs (H7 line) were supplied by Geron Corporation. Human ESCs were 
cultured on Matrigel-coated 6-well plates in mouse embryonic fibroblast-conditioned 
medium (MEF-CM) supplemented with 8 ng/mL recombinant human bFGF, 50U/mL 
penicillin and 50µl/mL streptomycin. The details of sub-culturing of the H7 cells and 
their differentiation through embryoid bodies (EBs) were done as described by Geron 
(http://www.geron.com/PDF/scprotocols.pdf) with the exception that mitomycin C was 
used for mitotic inactivation of MEF instead of using irradiation. 
Briefly, MEFs were isolated from 13 days embryos of MF-1 strain of mice and then 
were expanded in culture and inactivated at passage 3. 12x10
6 
of inactive cells were 
attached overnight in 15% FCS (fetal calf serum, non-heat-inactivated) containing 
medium on T225 flask.Subsequently the cells were washed and cultured in medium 
known as a “human ES cell medium” supplemented with 4ng/mL bFGF. The human ES 
cell medium was a mixture of KO-DMEM, supplemented by 20% serum replacement 
(KOSR), 1mM L-glutamine, 0.1mM Non-essential amino acids, 0.1mM β-
mercaptoethanol,50U/mL penicillin and 50µM/mL streptomycin. 150 mL of MEF-CM 
was collected daily from each T225 flask which was then pooled, filtered and aliquoted 
for storage at -20
0
C. The undifferentiated H7cells were fed with MEF-CM daily which 
was further supplemented with 8ng/mL bFGF. 
Before splitting or differentiation into cardiomyocytes, cultures of H7 cells were treated 
with with collagenase IV (200U/mL) for 5-10 minutes at 37
0
C, and followed by 
mechanical dislodgement. In order to induce differentiatiation from EBs, the colonies of 
undifferentiated H7 cells were mechanically broken up into smaller clusters by scraping 
the well with the tip of a 5-mL pipette. The small clusters that retained within a pipette 
tip were pipetted and cultured in suspension. The 20% KOSR in ES cells medium was 
substitute with 20% non heat-inactivated FCS, and cells were maintained in this 
medium. Following 4 days of differentiation, EBs were plated out onto 0.5% gelatine-
coated glass or plastic and were used for experiments from day 9-12 of differentiation 
onwards. 
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2.3 Scanning Ion Conductance Microscope (SICM) 
 
The scanning ion conductance microscope (SICM) is a technique and instrument 
developed to investigate both the functional properties and topography of intact cells 
(Korchev et. al, 1997). SICM have been demonstrated to measure rate, rhythm and 
amplitude of contraction (Figure 2.1A) of individual cells and cardiomyocytes clusters 
in culture with high accuracy (Gorelik et al. 2006, Gorelik et al. 2006). In addition, 
SICM is employed to image the surface of intact live cells with high topographic 
resolution (Figure 2.1B). The SICM is based on scanning a micropipette over the cell 
surface whereby the ion current between the pipette and the solution in the dish is 
feedback to the controller to maintain the pipette-sample distance constant, as the 
current decreases as the pipette moves closer to the cell membrane. The micropipettes 
can be used also to perform a patch clamp to characterize ion channels (Gorelik et. al, 
2002). The system probe consists of a glass micropipette filled with electrolyte and an 
electrode plugged into it which is connected to an Axopatch 200A patch clamp 
amplifier with a headstage (CV201A, Axon Instrments, Inc., Union City, USA) to 
detect the ion current passing through the pipette tip. Then the amplified ion current is 
digitized and fed into the feedback and scan control system. The control system 
generates the X, Y, Z scanning signals which are used to drive the three -dimensional 
piezo translation stage (Tritor, Piezo system Jene, Germany) where the micropipette is 
mounted. 
The data acquisition system records both the lateral and vertical positions of the 
translation stage, which then can be used to generate the topographical image of the cell. 
The scanning micropipettes were pulled using a laser-based puller (P-2000, Sutter 
Instrument Novata, CA) to produce pipette with approximately 200 nm in diameter. The 
time required to scan an area of 40-60μm2 was about 15-20 minutes. The medium L-15 
was used as a bath and micropipette solutions. 
 
2.3.1 Measurement of contraction using SICM 
 
During contraction of a cardiomyocyte, as the cell surface rises, the sample stage will 
also be displaced vertically. The SICM microscope keeps the separation distance 
between the tip of the micropipette and the cell surface constant, which is controlled by 
the feedback signal. Having positioned the pipette at the very top of a cell, vertical 
displacement of the stage can be recorded as a displacement that reflects cell shape 
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change during contraction (Figure 2.2A). The vertical displacement of individual cells 
and clusters of cardiomyocytes was recorded. The bile acid taurocholate was added to 
the culture medium and the effect of taurocholate on rate and amplitude of contraction 
was detected and recorded. The L-15 medium was used as bath and micropipette 
solution, so that salt concentration gradient potentials and liquid junction potentials 
were not generated. 
For ESCM, imaging of various ESCM layer zones and contracting cardiomyocytes was 
performed (Figure 2.2B).  
The vertical displacements recorded were viewed using Clampfit 10.2 Software. The 
recorded vertical displacements can be converted into histogram showing the average 
traces. 
In obtaining the data, there was no inter and intra observer variation. The investigator 
was blinded when obtaining and analysing the data. 
 
 
 
 
 
 
 
Figure 2. 2: Principal schematic diagram of Scanning ion conductance microscope. 
  
Scanning ion conductance microscope (SICM) is used to record vertical cell 
displacement (A) and to scan the surface of living cells (B). 
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2.4 3H-Taurocholate (3HTC) Influx Assay of Neonatal rat cardiomyocytes 
 
Cardiomyocytes seeded into 24-well plates were incubated in parallel at 4
o
C or 37
o
C 
with 250 µl of influx media consisting of 0.2 µM 
3
HTC in physiological L-15 medium 
(Gibco, Parsley, UK) for 5-60 minutes. Influx activity was stopped by washing each 
well with 500 µl of ice-cold 1 mM TC, repeated three times. Subsequently, cells were 
lysed with 250 µl of RIPA buffer (150 mM NaCl, 10 mM Tris HCl pH 7.2, 0.1% SDS 
(w/v), 1.0% Triton x-100 (v/v), 1% Deoxycholate (w/v), 5 mM EDTA), 175 µl of which 
was mixed with 2 ml of scintillation cocktail and used to count lysate radioactivity in a 
Beckman Coulter LS6500 counter and the remainder used to assay protein quantity for 
normalisation using the Pierce Chemical BCA protein assay kit (Cramlington, UK). 
Then the same experiment was performed on primary human hepatocytes (provided by 
Dr. Shadi Abu-Hayyeh). 
 
2.5 3H-N-Methylscopolamine (3H- NMS) binding assay in Neonatal rat 
cardiomyocytes 
 
For the binding assay, cardiomyocytes were seeded and grown in T75 flasks. On the 
third day, cells were scraped in cold PBS using a cell scraper, followed by 
centrifugation of cells in suspension at 1200rpm for 5 minutes. The cell membranes was 
washed with PBS and centrifuged at 1200rpm for 5 minutes. The pellets obtained 
contained the cell membranes of cardiomyocytes which were then frozen in liquid 
nitrogen and stored in a -80
o
C freezer.  
Thawed membranes were incubated at room temperature in assay buffer (25 mM 
phosphate buffer saline, 5 mM MgCl2, pH 7.4). The protein content of the cell 
membrane was measured using the BCA Protein Assay Kit. 20 µg protein of the cell 
membranes isolated from NRCM were incubated for 2 hours with 0.1-10 nM 
3
H-N-
methylscopolamine (
3
H-NMS) in the presence of 0.01 – 1000 μM of carbachol or 
taurocholate. Nonspecific binding was determined in the presence of 10 µM atropine.  
and reactions were terminated by vacuum filtration through GF/B glass fibre filters 
(Millipore, Schwalbach, Germany). 
This experiment was done with the assistance of Dr. Nikolaev Viacheslav. 
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2.6 Assessment of beating frequencies 
 
Single NRCM or small clusters (network of 1 to 3 cells) of cells were chosen for this 
experiment.  Beating frequencies were visually recorded according to the method of 
(Clark et al. 1991). The muscarinic antagonist carbachol and the selective M1 to M3 
receptor blockers were used to study the involvement of muscarinic receptors in bile 
acid-induced cardiomyocyte dysrhythmias. In addition, cells were also treated with the 
Gi/o blocker pertussis toxin and with the TGR5 agonist oleanolic acid.  
Cardiomyocytes were pre-incubated at 37
o
C humidified with 5% CO
2
 with 1 µM 
pirenzepine (M1 blocker) , 1 µM 4-DAMP (M3 blocker), 1 µM methoctramine (M2 
blocker), 500 nM pertusiss toxin, 100 µM carbachol or 100 µM oleanolic acid for 30 
minutes ahead of bile acid treatment. Then the contraction rate of the cardiomyocytes 
was counted under a light microscope. Cardiomyocytes were treated with 0.2 or 1 mM 
taurocholate for 10 minutes. The contraction rate was counted again. 
For TC and CCh dose dependent contraction experiment, each individual cell was 
treated with range of concentration 0.001 to 1000 µM for 10 minutes. 
 
2.7 Optical recording of Calcium transients 
 
The cardiomyocytes produced beat-to-beat calcium movements that were recorded in 
real time using a fluorescent indicator (Ranu et. al, 2002; McCall et. al, 1998). The cells 
were cultured on glass coverslips. The characteristics of Ca
2+
 transients were assessed 
optically after staining the preparations with Fluo-4 acetoxymethyester (Fluo-4 AM).  
The cells were loaded with 100 µL of 5 μg/ml Fluo-4 and incubated at 37°C for 1 hour. 
The procedure for recording of calcium transients in ES cells derived cardiomyocytes 
and neonatal rat cardiomyocytes are described as below.   
 
Recording of Calcium transients in ESCM 
The ES cells derived-cardiomyocytes were loaded with Fluo-4 in medium of 
Leibovitz‟s L15 at room temperature. Cells were washed five times to remove excess 
dye and then cells were incubated for 20 minutes for complete cleavage of dye into the 
cells (Lopez et al. 1995). Fluctuations of Ca
2+ 
were recorded by exciting fluo-4 at 450-
480 nm and followed by detection of emitted fluorescence at 520 nm using an 
intensified CoolView IDI camera system (CCD, Photonic Science, Sussex,UK) coupled 
to a Nikon TE-2000 inverted microscope. Images were controlled and analysed by 
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Image-Pro Plus software (Media Cybernetics, Wokingham, UK). Images of cells before 
addition of drugs were saved as control. Taurocholate was added at specific times. 
Images were cropped and saved as colored movies. 
 
Recording of Calcium transients in Neonatal rat cardiomyocytes 
Experiments were performed with 3-day-old preparations. Cells were loaded with of 
Fluo-4 AM were washed with Hanks Balance Salts Solution (HBSS) solution. During 
the experiments, preparations were continually superfused at 36°C with HBSS 
containing (mmol/L) NaCl 137, KCl 5.4, CaCl2 1.3, MgSO4 0.8, NaHCO3 4.2, KH2PO4 
0.5, NaH2PO4 0.3 and HEPES 10. The solution was titrated to pH 7.40 with 1 mol/L 
NaOH. Changes in fluorescence corresponding to intracellular Ca
2+
 changes were 
assessed using a fast CMOS camera (MiCAM Ultima, Scimedia) coupled to a Nikon 
inverted microscope Ti/U equipped for epifluorescence (magnification 20x, N.A 0.75). 
This system is able to record calcium activity in an area measuring 1 mm x 1 mm with a 
spatial resolution of 5 μm and a temporal resolution of 1 ms. The assessment of calcium 
transient in a given preparation was limited to 2-5 recordings, 4 s each, in order to avoid 
phototoxic effects of the dyes. Optical raw data were analyzed using dedicated software 
from the camera manufacturer (BV_Analyze V8.02, SciMedia). After offset correction 
the maximum dF/F was setting at 10% in order to scale the traces with the Ca
2+ 
amplitude measured in
 
pre-treated preparations. Images of cells before addition of drugs 
were saved as controls. Then taurocholate was added at specific times. Images were 
cropped and saved as colored movies. After measuring Ca
2+
transients in normal 
superfusion solution (HBSS), the same preparations (control, scramble and siRNA M2) 
were superfused with an HBSS solution containing TC 0.2 mM and Ca
2+
 transients were 
recorded again after 20 min perfusion in the same conditions. Cardiomyocyte clusters 
were included in the analysis if they fulfilled the following criteria: (i) the clusters had 
spontaneous beating activity, (ii) the clusters consisted only of cardiomyocytes and (iii) 
the clusters had a maximum dimension of 100x100 μm.  
 
2.8 FRET imaging of cAMP 
 
Cyclic adenosine monophosphate (cAMP) is a second messenger that activates cyclic 
protein kinase A (PKA) and nucleotide regulated ion channels. For real time monitoring 
of cAMP in living cells, fluorescence resonance energy transfer (FRET) technique is 
employed. In order to detect cAMP, genetically encoded fluorescent cAMP indicator 
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Epac2 (exchange protein directly activated by cAMP) is used. The Epac molecule is 
sandwiched between the cyan fluorescent protein (CFP) and yellow fluorescent protein 
(YFP); FRET is used to measure the fluorescence energy transfer between the two 
fluorescent proteins. In its inactive form, Epac is folded in the presence of low cAMP 
levels. When the intracellular cAMP level rises, the cAMP molecules bind to Epac and 
unfold the proteins which make the CFP-Epac-YFP sandwich fall apart.  
The FRET imaging of cAMP in intact neonatal cardiomyocytes was performed in cells 
infected for 48 h with Epac2-cAMPs adenovirus (Nikolaev et al. 2005). Prior to the 
experiment cells were washed twice and measured at room temperature in FRET buffer. 
Cells were measured in the presence of 0.2 mM TC or 0.1 mM CCh for 5 minutes and 
then stimulated with 100 nM of isoproterenol. The imaging system was built around a 
Nikon TE2000 microscope equipped with a mercury lamp (HB0103W/2, Osram), 
EX436/20 excitation filter combined with DM455 dichroic mirror. Cell fluorescence 
was split into YFP and CFP channels using a DualView (Optical Insights) equipped 
with 535/40 and 480/30 emission filters and monitored by the ORCA-ER CCD camera 
(Hamamatsu, Welwyn Garden City, UK). FRET ratios were corrected and analyzed 
using Origin software (OriginLab Corporation, Northampton, MA). 
 
2.9 Immunofluoresence  
2.9.1 TGR5 immunostaining 
 
For immunofluorescent studies, isolated Kupffer cells and cardiomyocytes were seeded 
on glass coverslips and fixed in 100 % methanol (5 min, -20 °C). Cryosections (5 µm) 
of perfused rat liver were prepared with a Leica cryotome, air-dried for 1 hour and fixed 
in 100 % methanol (5 min, -20 °C). An antibody against the C-terminus (aa 306-329) of 
rat TGR5 was used at 1:150(Keitel et al. 2007). A Cyanin-3 conjugated secondary 
antibody (Jackson Immuno Research Laboratories, West Grove, PA) was diluted 1:500 
and Hoechst 34580 (Invitrogen) was added at 1:10,000 respectively. Samples after 
immunostaining were analyzed on Zeiss LSM 510 META confocal microscope (Zeiss, 
Oberkochen, Germany) using the same settings for all samples. 
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2.9.2 Fxr immunostaining pre and post bile acid treatment 
 
The cells attached to a glass coverslips were rinsed with PBS and fixed for 10 minutes 
with 4% (v/v) formaldehyde (Sigma Aldrich). The cells were then washed with PBS 
and permeabilized for 40 minutes with 0.2% Triton X-100 (v/v). After washing with 
PBS, the cells were blocked with 0.1% of bovine serum albumin (w/v) for 15 minutes. 
The cells were probed overnight at 4
o
C with the antibodies specific to fxr (FXR/NR1H4 
Human Monoclonal Antibody, 1:100,R&D Systems). After washing, the cells were 
incubated with fluorescein-conjugated secondary antibody anti-mouse to detect the 
antigen. To stain the nuclei, cells were incubated with DAPI for 20 minutes at 37
o
C. 
The cells were washed with PBS and the coverslips were mounted on glass slide using 
Vectashield. 
2.10 siRNA silencing of chrm2 
Cells were seeded in 12-well plates in 1 ml of phenol red free DMEM supplemented 
with 2% DCC-FBS without antibiotics. Cardiomyocytes at 60-70% confluency were
 
transfected with siRNA targeted to chrm2 and scramble siRNA as a control using 
DharmaFECT1. Both siRNA-M2 and scramble siRNA stock solution were diluted with 
1X siRNA buffer from 20 µM to 2 µM. For each well, a transfection mix was prepared 
as follows: in tube 1 100 nM of siRNA (50 µl of 2 µM siRNA) was added to 50 µl of 
Opti-MEM reduced serum medium and in tube 2 3 µl of DharmaFECT1 reagent was 
added to 97 µl of Opti-MEM reduced serum medium, both solutions were mixed gently 
and incubated at RT for 5 minutes. The content of tube 1 was added to tube 2, gently 
mixed and incubated for 20 minutes at RT. The transfection mixture was added to each 
well. After 48 hour the transfection mixture and media was removed and replaced with 
phenol red free DMEM with 2% DCC-FCS.  To assess chrm2 siRNA knockdown, cells 
were lysed with lysis buffer (Qiagen, UK) for RNA extraction and then qRT-PCR. 
 
2.11 RNA manipulation and Gene Expression 
2.11.1 Isolation of total RNA from cells and tissues 
Total RNA was isolated from rat neonatal cardiomyocytes and liver tissue using 
RNeasy Mini kit (Qiagen Inc.). RNA samples were quantitated using nanodrop (TM800 
Spectrophotometers). 
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2.11.2 cDNA synthesis 
500ng of RNA was reverse transcribed using the Advantage RT-for-PCR kit for qRT-
PCR (Clontech, Takara Bio.) following the manufacturers instructions.  
 
2.11.3 qRT-PCR primer design 
Primers for the transporters were designed using the Primer Express software program 
(PE Applied Biosystems Foster City, USA) (Table 2.2), crossing intron exon boundaries 
where possible, to eliminate the possibility of amplifying genomic DNA. Primers were 
dissolved in DEPC-treated water to a final concentration of 100 pmol/µl. 
 
 
Gene Forward primer Reverse Primer 
l19 
 
ATCTCAAGCAAACACCATTCC 
 
TTGATGATGCTGTCTAGTACC 
chrm
2 
TTGTGGCTGGATCCCTCAGT 
 
TGGCGGTTGACTTTAATGGAA 
 
fxr TGACAAAGAAGCCGCGAA 
 
CACACAGCTCATCCCCTTTTATT 
 
shp 
 
CCTTGGCTAGCTGGGTACCA 
 
 
GTCCCAAGGAGTACGCATCTT 
 
ntcp 
 
ATCTCAAGCAAACACCATTCC 
 
GATCATGCCTCCCTTAAGGA 
mdr2 GAAGGAATGTGGCCGGGATAA GGCCCGGGTGGGATAAT 
mrp2 CTGGAGCTGGTTGGAAACTTG CGTCCCCGGTTAAGGTTTTT 
 
Table 2. 2: Primers for Real time Quantatitive Polymerase Chain reaction (qRT-
PCR). 
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2.11.4 Gene Expression Analysis using Real Time Quantitative PCR 
 
Real time Quantatitive Polymerase Chain reaction (qRT-PCR) was employed to analyze 
gene expression. SYBR-Green is a dye that fluoresces upon intercalatation with DNA 
synthesised from the target cDNA template. The fluorescent signal emitted is detected 
in each cycle of PCR and is relative to the amount of the target cDNA present in the 
reaction sample. For each reaction sample, a cycle threshold (Ct) value is determined. A 
Ct value is corresponding to the number of PCR cycles needed to generate a fluorescent 
signal within the linear phase reaction. For each gene reaction, the gene expression is 
calculated relative to the housekeeper gene, and in all experiments in this thesis the 
housekeeper gene was l19. 
 
After cDNA synthesis, 500ng of cDNA was amplified by Real-time QPCR (qRT-PCR) 
using primers for the relevant gene or for l19 in separate wells with 2x Jump-start 
SYBR Green Taq ReadyMix (Sigma), 10 µM of gene specific forward and reverse 
primers are made up to a total volume of a 25l with DEPC-treated water. L19 gene was 
used as a control to normalise the data for the difference in starting material, efficiencies 
of RNA extraction and reverse transcription (RT) reactions for each sample. The PCR 
was performed on the MJ Opticon2 (Bio Rad) in 96 well plates with initial steps of 2 
min at 94C, 15 seconds at 95C, 30 seconds at  60C and 30 seconds at 72C for a total 
of 40 cycles. PCR amplification of each sample was performed in triplicate to minimise 
pipetting error. 500ng of rat liver cDNA was used as a positive control and a non-
template control was also included for each run. 
 
In this thesis, gene expression (Ct) was calculated by substracting the mean of Ct 
value for the l19 (triplicate) from the mean of Ct value for the gene of interest 
(triplicate).  Subsequently the Ct calculation was performed by subtracting a selected 
cDNA Ct from the Ct of each sample. The Relative expression standard error of the 
mean (SEM) was calculated based on the mean Ct values of each sample with 
treatment relative to mean Ct of control or untreated sample.  
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2.12 Protein Analysis 
2.12.1 Protein Extraction from cells for western blot analysis 
Cell were grown in 12-well plates and treated appropriately. Cells were washed with ice 
cold PBS and whole cell extracts were lysed in 100 µl of ice-cold RIPA buffer 
containing protease inhibitors. Cells were scraped and transferred to 1.5 ml tubes.  The 
cell lysates were sonicated for a few seconds and centrifuged at 10,000 RPM for 15 min 
at 4°C to remove cell debris.  
 
2.12.2 Quantification of Protein Concentration 
Protein concentration was determined using the BCA protein assay kit. Briefly, the kits 
used a principal of protein in alkaline solution causing reductrions of Cu
2+
 to Cu
1+ 
and 
then the Cu
1+ 
cholates with bicinchoninic acid to form a purple solution. BSA protein 
standard diluted with RIPA buffer ranging from 0-2000 µg/ml was used as standards. 
Reactions were performed in 96-well plates. Standards were performed in duplicate and 
samples were performed in triplicate. 12.5 µl of samples or standards was pipetted into 
each well .The BCA reagent was prepared by adding 50 parts of Reagent A and 1 part 
of reagent B. 100 µl of BCA reagent was added was added to each well of 
standard/sample. Plates were incubated for 30 minute at 37
o
C and then absorbance was 
measured at 592nm. 
2.12.3 Protein Extraction from tissue for western blot analysis 
Tissues were dissected, washed in PBS, flash frozen in liquid hydrogen and stored at -
80
o
C. The tissues were cut into small pieces and homogenized in 500 µl of ice-cold 
RIPA buffer containing protease inhibitors.   
2.12.4 Western Blot 
The Mini-trans Blot System (Invitrogen) was used to transfer proteins from the 
resolving gel to nitrocellulose membranes. 30 µg protein samples were fractionated by 
12% SDS-polyacrylamide gels electrophoresis, blotted onto a nitrocellulose membrane 
(Millipore Cor., Bedford, MA, U.S.A.). Membranes were blocked for 1 h at room 
temperature with 5% nonfat milk in PBS containing 0.05% Tween-20 and incubated 
with antibodies specific to fxr (FXR/NR1H4 Human Monoclonal Antibody, 
1:1000,R&D Systems) or β-Actin overnight at 4°C. Afterward the blots were visualized 
using the ECL system (Amersham Biosciences). Blots were exposed to 
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autoradiographic X-ray film and bands were quantified with ImageJ software and 
normalised again β-Actin. 
 
 
2.12.5 Statistics 
Statistical method is used to analyse or summarize data collected. In biological and 
medical research, two or more groups of data collected could be compared usin 
statistical analysis that involves probability (P) (Fraker et. al, 2001).This can be 
achieved by applying a test such as Student‟s T-test and analysis of variance (ANOVA). 
Student‟s T-test is used when two sets of different samples are analysed, while ANOVA 
is normally used when the study is involving more than two groups of variable data. 
However one way ANOVA was also performed to confirm the analysis obtained from 
Student‟s T-test. 
In this thesis values are presented as mean SD or mean SEM for replicates. Microsoft 
Office Excel software was used to perform t-tests and ANOVA for determination of 
statistically significant differences in mean. In all results, p<0.05 is considered 
statistically significant. 
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Chapter 3 
Stage of differentiation of fetal cardiomyocytes influences 
susceptibility to bile acid-induced dysrhythmias 
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3 Stage of differentiation of fetal cardiomyocytes influences 
susceptibility to bile acid-induced dysrhythmias. 
 
3.1 Introduction 
 
The discovery of embryonic stem cells (ESC) has lead to the development of techniques 
to differentiate stem cells into several types of cells including cardiomyocytes by 
growing them as embryoid bodies (EBs). Between 5 to 10 days after plating 
spontaneous rhythmic beating is detected in EBs and the proportion of contracting EBs 
continues to increase over the next 10 days. Throughout differentiation, cardiac 
myocytes derived from ESCs have been reported to show similar contractile, electrical 
and signaling properties as are seen in in vivo cardiac development (Hescheler et al. 
1997, Kehat et al. 2001, Xu et al. 2002, Mummery et al. 2002, Brito-Martins et al. 
2008). The first success in derivation of ESC-CM was reported in 1990s from the inner 
cell mass of blastocysts. Now more than 400 lines of human ESCs are available in 
international stem cell banks (Jensen et al. 2009).  
 The emergence of embryonic stem cells-derived cardiomyocytes (ESC-CM) has raised 
hope among cardiac researchers and clinicians that these cells potentially can be used in 
cardiac repair (Klug 1996, Laflamme 2007), but there is still a lot to be done before 
these cells can be used at a clinical level (Boheler 2009). However ESC-CMs have been 
developed into a model system for cardiac research mainly because it provides insights 
into cardiomyogenesis. Another interesting potential of ESC-CM, especially human 
cells, is that they can be as a tools for understanding or screening of drugs or 
metabolites. Other cell culture models of cardiac cells such as primary adult myocytes 
and fetal/neonatal myocytes isolated from rodents are stable in culture for only a few 
days or weeks respectively (Louch et al. 2004, Piper et al. 1988).  
On the contrary, ESC-CM survive in culture over months and they are used as a cardiac 
model for investigation of cardiac development, pathology, drug discovery and 
toxicology. The maintenance of contracting mouse ESC-CM (mESC-CM) and human 
ESC-CM (hESC-CM) has been established in collaboration with Professor Harding‟s 
group. For hESC-CM, the cells have been grown and maintained up to 7 months which 
was the longest period studied in our laboratory. In addition, the maturation of the cells 
has been shown in terms of morphology and membrane currents (Harding et al. 2007, 
Sartiani et al. 2007).  
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In this chapter, ESC-CM, both human and mouse, were used as a model to investigate 
the sensitivity of ESC-CM to bile acids during maturation. Moreover, this chapter 
demonstrates the potential of ESC-CM as a fetal model system to investigate the 
aetiology of intrauterine death in intrahepatic cholestasis in pregnancy (ICP). The 
mechanism of fetal death in ICP is poorly understood; there is no evidence of utero-
placental insufficiency and usually the fetal autopsy is normal (Costoya et al. 1980). 
Arrhythmia has been hypothesized to cause fetal death in ICP since an abnormal fetal 
heart rate (≤100 or ≥180 beats/minute) was observed (Reid et al. 1976, Laatikainen & 
Tulenheimo 1984, Laatikainen 1975) and atrial arrhythmias have been reported in the 
fetus of a woman with ICP (Al Inizi et al. 2006).  
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3.2 Effect of Taurocholate (TC) on contraction of mESC-CM at different stages 
of differentiation 
The differentiation of mESC-CM can be divided into early, intermediate and terminal 
stages (Boheler et al. 2002). In this study, the effect of TC on the contraction of mESC-
CMs from D3 was compared between three different stages of differentiation. Another 
mESC-CM cell line, E14Tg2a line was used to confirm the effect of TC on contraction. 
Scanning Ion Conductance Microscopy (SICM) was employed to record the vertical 
displacement of contraction with and without TC.  Cells were treated with a low 
concentration of TC; 0.1 mM and a high concentration of TC; 1.0 mM. 
 
3.2.1 Effect of TC on contraction of ES-derived cardiomyocytes (D3 line) before 
and after addition of different concentrations of TC recorded using SICM 
3.2.1.1 mESC-CM: early stage of differentiation 
Prior to addition of TC, the cardiomyocytes derived from ESCs at early stage of 
differentiation (day 7 to 10) contracted spontaneously and rhythmically at a rate of 29.0 
± 1.7 beats per min (bpm, mean ± SD, n=6)(Figure 3.1). Addition of 0.1 mM TC to the 
culture medium caused a significant reduction in the rate of contraction, which reduced 
significantly to 21.5 ± 1.6 bpm (P<0.05) in 6 individual experiments (n=6). Further 
reduction in the rate of contraction to 11.6 ± 1.6 bpm (P<0.05, n=6) was observed with 
the addition of 1 mM TC, (Figure 3.1). Although there was an increase in the rate of 
contraction following transfer to TC-free medium, it was not fully reversible and there 
was a reduction of the rate of contraction as compared to control (P<0.05, Student t-test) 
and other stage of differentiation (P<0.05, ANOVA). 
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Figure 3. 1: Measurement of contraction of mESC-CM (D3) in early stages of 
differentiation. 
Representative traces of the influence of the addition of 0.1mM and 1.0mM TC on the 
rate and amplitude of contraction of mESC-CM. 
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3.2.1.2 mESC-CM: intermediate stage of differentiation 
Figure 3.2 shows representative SICM recordings of the amplitude of contraction of 
mESC-CM before and after the addition of TC during intermediate stage of 
differentiation. The initial rate of contraction prior addition of TC was 36.0 ± 1.9 bpm 
(n=7) (Figure 3.2). When 0.1 mM TC was added to the culture medium, a significant 
decrease in rate of contraction to 29.7 ± 3.6 bpm was observed (P<0.05, Student‟s t-test, 
n=7) (Figure 3.2). A further reduction in the rate and amplitude of contraction was 
observed with TC 1.0 mM, 7.1 ± 5.4 bpm (P<0.05). Following transfer of cells into TC-
free medium, we did not observe a full recovery of cell contraction and there was still a 
slight reduction in amplitude as compared to untreated control cells. 
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Figure 3.2: Measurement of contraction of mESC-CM (D3) in intermediate stages 
of differentiation. 
Representative traces of the influence of addition of 0.1mM and 1.0mM TC on the rate 
and amplitude of contraction of mESC-CM. 
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3.2.1.3 mESC-CM: terminal stage of differentiation 
Prior to the addition of TC the mESC-CMs contracted with a normal rate and  rhythm of 
33 ± 2.0 bpm (mean ± SD; P<0.05, Student‟s t-test, n=7) (Figure 3.3). Unlike in the 
early and intermediate stages, the addition of 0.1mM TC had no effect on rate of 
contraction at the later stage of differentiation, and it remained at 33.8 ± 1.6 bpm. The 
addition of 1.0 mM caused a reduction of rate of contraction to 28.6 ± 2.7 bpm. 
Nevertheless, changes in contraction were fully reversible following transfer to the TC-
free medium (Figure 3.3).  
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Figure 3.3: Measurement of contraction of mESC-CM (D3) in intermediate stages 
of differentiation. 
Representative traces of the influence of addition of 0.1mM and 1.0mM TC on the rate 
and amplitude of contraction of mESC-CM (D3) in the terminal stage of differentiation. 
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3.2.2 Influence of TC on amplitude of contraction of ES-derived cardiomyocytes 
(D3 line) 
3.2.2.1 Interbeat interval 
The rate of contraction was expressed as a beat to beat interval and presented in the 
form of a histogram to facilitate arrhythmia analysis as described previously (Gorelik et. 
al, 2003). In control untreated cells at all stages of differentiation the peak of the 
histogram was narrow and was demonstrated consistently in every experiment (Figure 
3.4A-C).  
Addition of 0.1mM and 1.0mM TC to the culture medium of cells in the early stage of 
differentiation showed abnormal histogram (Figure 3.4A, middle graph and Figure 
3.4A, right graph). The effect of 1mM TC in early stage was not reversible as 
approximately half of the cells stopped beating. 
When 0.1mM TC was added to the culture medium, ES-derived cardiomyocytes at the 
intermediate stage of differentiation showed two peaks reflecting arrhythmia (Figure 
3.4B, middle graph). A stronger effect was observed with the high concentration of TC 
(1mM) which caused severe arrhythmia with long pauses between peaks (Figure 3.4B, 
right graph). 
At the terminal stage of differentiation, administration of 0.1mM TC did not affect the 
beat to beat interval (Figure 3.4C, middle graph). However, addition of 1.0mM TC 
resulted in two peaks consistent with arrhythmia (Figure 3.4C).
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Figure 3.4: Histogram of the interval of time between beats of mESC-CM. 
Representative histogram of the interval of time between beats of mESC-CM (A) in 
the early stage of differentiation. (B) In the intermediate stage of differentiation. (C) 
In the terminal stage of differentiation.  
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3.2.3 Changes in amplitude of contraction compared to control 
The changes in amplitude of contraction with administration of TC recorded using 
SICM (as shown in Figure 3.1-3.3) were compared to the control values and expressed 
as percentage of the control for each stage of differentiation (Figure 3.5).  
The administration of 0.1mM TC to the culture medium of cardiomyocytes at the early 
stage of differentiation caused a decrease of 28% (P<0.05) in the amplitude of 
contraction, whereas 1.0mM TC caused a 61.5% decrease (P<0.05). Following transfer 
to the TC-free medium, the amplitude of contraction recovered by up to 20%. 
In cells at the intermediate stage of differentiation, the addition of 0.1mM TC to cells 
caused a 35% reduction (P<0.05) while 1.0mM TC caused a 53% reduction in 
contraction amplitude (P<0.05). These effects were recovered by up to 30% when 
transferred to the TC-free medium.  
The addition of 0.1 mM TC to the cells in the terminal stage of differentiation did not 
influence the amplitude of contraction. Adding 1.0 mM TC affects the rate of 
contraction as shown in Figure 3.3C. However the amplitude of contraction was not 
significantly altered (Figure 3.5). 
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Figure 3.5: Effect of 0.1mM and 1.0mM TC on the amplitude of contraction in 
mESC-CM at the early, intermediate and terminal stages of differentiation. 
This is represented as a percentage of the amplitude of contraction in cells prior to the 
addition of TC (designated controls). The extent to which the amplitude of contraction 
returns to normal after transfer of cells into the TC-free medium is also shown. 
(*P<0.05, Student‟s t-test compared to control). (#P<0.05, ANOVA compared between 
stages of differentiatioan). (n=6 early stage; n=7 intermediate stage; n=5 terminal stage).  
 
 
 
 
 
 
 
 
 
  * 
 * 
  * 
 * * 
# 
  89 
3.2.4 Effect of TC on contraction of ES-derived cardiomyocytes (E14Tg2a line) 
before and after addition of different concentrations of TC 
Cardiomyocytes derived from ESCs of the E14Tg2a line demonstrated disruption of 
rhythm and amplitude of contraction in the presence of 0.1-1.0 mM TC and even 
following a transfer back to the TC-free medium (Figure 3.6). That was similarly 
observed in the early stage of differentiation of the ESCM from the D3 line. 
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Figure 3.6: Effect of 0.1 mM and 1.0 mM TC on the amplitude of contraction in 
mESC-CM derived from E14Tg2a line at the early and late stages of 
differentiation. 
This is represented as a percentage of the amplitude of contraction in cells prior to the 
addition of TC (designated controls). The extent to which the amplitude of contraction 
returns to normal after transfer of cells into TC-free medium is also shown. (*P<0.05 
compared to control, ANOVA and Student‟s t test). (n=5 early stage; n=4 terminal 
stage). 
 
 
 
 
 
 
 
 
 
 
 
 * 
 * 
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3.2.5 Intracellular Calcium dynamics in mouse ESC-derived cardiomyocytes 
after loading with Fluo-4 
Figure 3.7 shows an example of recordings of intracellular Ca
2+
 dynamics of mouse 
ESC-CM at the intermediate stage of differentiation after loading with Fluo-4. Prior to 
addition of TC, the network of cells contracted synchronously and this was revealed by 
the standard bright-field microscopy and at the same time synchronous Ca
2+
 transients 
were recorded throughout the cluster (Figure 3.7, left panel). On this figure images of 
fluorescence are shown recorded pre- (a), at the peak of (b) and post- (c) calcium 
transient, which is indicated by an arrow. Administration of 1 mM TC to a cluster of 
cells altered Ca
2+
 dynamics triggering an increase in the frequency of Ca
2+
 waves, 
which is a sign of Ca
2+
 overload (Figure 3.7, central panel). After approximately 10 min 
of TC treatment, the cells showed markedly raised Ca
2+
 in diastole and strikingly 
decreased transient amplitude in systole (Figure 3.7, right panel). 
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Figure 3. 7: Intracellular Ca
2+ 
dynamics of mESC-CM loaded with Fluo-4.  
The left hand panel represents the contraction of mESC-CM before addition of TC to 
the culture medium. The images are taken at time points before (a), at the peak of (b) 
and after (c) the calcium transient. The central panel shows contraction following 
addition of 1mM TC to the culture medium. The right hand panel demonstrates the 
alterations in calcium transients that were observed after 10 min following the treatment 
with 1mM TC. The bottom panel of the figure shows recordings of Ca
2+ 
transients at the 
points indicated by the two arrows on the top diagram. Scale bar, 40 μm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
b 
c 
Control 1.0 mM TC, 1 min 1.0 mM TC, 10 min  
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3.3 Effect of bile acid on contraction of human ESC-derived cardiomyocytes (H7 
line) 
Vertical displacement of human ESC–derived cardiomyocytes was recorded pre- and 
post-administration of TC at the early (<30 days) and late (>30 days) stages of 
differentiation using the SICM microscope. The effect of 0.1 and 1.0 mM TC were 
compared at the early and the late stages of differentiation.   
Table 2 shows the effect of TC from 13 to 72 days of differentiation of human ESC-
CM. At the early stage when cells were differentiating for 13-72 days, the addition of 
0.1 mM TC to the culture medium did have an effect on the rhythm and amplitude of 
contraction in some experiments. On the contrary, cells at 42-60 days of differentiation 
treated with 0.1 mM TC did not have any alteration in contraction, and only amplitude 
of contraction was reduced in one experiment. Addition of 1.0 mM TC to the early-
differentiated cells affected amplitude and rhythm in all experiments (Table. 2). 
However, in the late-differentiated cells TC at high concentration (1.0 mM) only 
affected the rhythm of contraction and the amplitude was changed only in one 
experiment (Table. 2). 
In addition the hESC-CMs at both early and late stages of differentiation were stained 
for sarcomeric protein specific cardiomyocytes markers. The hESC-CMs had positive 
staining for myocytes, myosin heavy chain (MHCα/β) and cardiac troponin I (Figure 
3.8).  
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Day of Development 
Effect of Bile acid 
TC 0.1 mM TC 1 mM 
Amplitude Rhythm Amplitude Rhythm 
13 Effect Effect Effect Effect 
13 No Effect Effect Effect Effect 
13 Effect Effect Effect Effect 
18 No Effect Effect Effect Effect 
18 No Effect Effect Effect Effect 
19 No Effect Effect Effect Effect 
19 Effect Effect Effect Effect 
24 No Effect Effect Effect Effect 
28 Effect Effect Effect Effect 
28 Effect Effect Effect Effect 
28 Effect Effect Effect Effect 
29 No Effect Effect Effect Effect 
29 No Effect Effect Effect Effect 
     
42 No Effect No Effect No Effect Effect 
43 No Effect No Effect No Effect Effect 
43 No Effect No Effect No Effect Effect 
43 No Effect No Effect No Effect Effect 
48 Effect No Effect Effect Effect 
54 No Effect No Effect No Effect No Effect 
60 No Effect No Effect No Effect No Effect 
60 No Effect No Effect No Effect No Effect 
71 No Effect No Effect No Effect No Effect 
71 No Effect No Effect No Effect No Effect 
71 No Effect No Effect No Effect Effect 
Table 3. 1: Effect of TC on hESC-CM. 
Effect of 0.1mM and 1.0 mM TC on amplitude and rhythm of hESC-CM between 13 
days to 71 days of differentiation. 
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                                        Early Stage      Late Stage    
  
Figure 3.8: Representative immunofluorescence images showing hESC-CM at 
early and late stages of differentiation stained positive for the cardiac specific 
markers troponin I (red) and myosin heavy chain /β (MHC/β, green).  
In hESC-CM at the late stage of differentiation, the mitotic marker Ki67 shows nuclear 
expression in proliferating cell (green, nuclear spotted pattern). The striations 
characteristic of the sarcomeric structures in hESC-CM can be seen. DAPI (blue) was 
used for nuclear staining. Scale bar, 20 μm.  
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3.3.1 hESC-CM: Effect of TC on rate and amplitude of contraction at early and 
late stages of differentiation 
Optical measurements of the contraction of human ESC-CM at the early stage of 
differentiation pre- and post-treatment with TC was shown in Figure 3.9. Prior to the 
addition of TC, cells contracted spontaneously and rhythmically. When 0.1 mM TC was 
added, changes in the rate of contraction were observed from 23.2 ± 4.8 bpm (mean ± 
SD) to 16.3 ± 1.6 bpm (n= 10; P<0.05, Student‟s t-test). Following the addition of 1.0 
mM TC, further reduction of the rate of contraction was observed, the contraction 
slowed down to 7.4 ± 2.7 bpm (n=6). Following transfer to TC-free medium, the rate of 
contraction recovered only slightly but no full recovery was observed. 
At the late stage of differentiation of hESC-CM 0.1 mM (27± 2.4 bpm) showed non-
significant effect on either the amplitude or the rate of contraction (Figure 3.10). 
Addition of 1 mM TC (25.2 ± 1.3 bpm) showed reduction in rate of contraction but the 
impact was significantly less (Figure 3.10) than observed at early stage. 
 
 
 
 
Figure 3. 9: Representative traces of contraction of hESC-CM at the early stage of 
differentiation (<30days).  
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Figure 3.10: Representative traces of contraction of hESC-CM at the late stage of 
differentiation (>30days).  
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3.3.2 hESC-CM: Effect of TC on amplitude of contraction 
3.3.2.1 Interbeat interval 
Figure 3.11 presents measurements of the interval between beats of contracting hESC-
CM at the early and the late stages of differentiation. In control untreated cells at early 
stages of differentiation, the interval between beats was characterized by a relatively 
narrow distribution on the histogram and it peaked at approximately 4 seconds, 
moreover it was demonstrated consistently in every experiment (Figure 3.11A-B). The 
addition of 0.1 mM TC to hESC-CM at the early stage of differentiation caused the 
appearance of the second peak on the histogram (Figure 3.11A). When 1.0 mM TC was 
added, the histogram remained abnormal which becoming more marked compared to 
control (Figure 3.11A). In contrast, at the late stage of differentiation neither 0.1mM nor 
1.0 mM TC affected the beat-to-beat interval of contracting hESC-CM. (Figure 3.11B) 
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Figure 3.11: Representative histogram of the interval between beats of contracting 
hESC-CM.  
Top panel: early stage of differentiation; Bottom panel: late stage of differentiation. 
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3.3.2.2 Changes in amplitude of contraction compared to control 
The changes in amplitude of contraction after addition of TC were compared to 
untreated/control which was expressed as 100% (Figure 3.12). When 0.1 mM TC was 
added at the early stage of differentiation, the amplitude of contraction decreased to 
88.1% ± 7.0% of control value, which is not a significant change. Further reduction was 
observed following the addition of 1.0 mM TC, the amplitude dropped to 57.9% ± 8.0% 
(P<0.05, ANOVA) of control. Following transfer of cells back to the TC-free medium, 
the amplitude of contraction recovered slightly to 63.3% ± 4.0% of control, however the 
change is not significant. At the late stage of differentiation, the cells were not 
significantly affected by the addition of either 0.1 or 1.0 mM TC.  
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Figure 3.12 : Effect of 0.1mM and 1.0mM TC on the amplitude of contraction of 
hESC-CM at the early and late stages of differentiation.  
This is represented as a percentage (%) change in the amplitude of contraction 
compared to that observed in cells prior to the addition of TC (designated controls). The 
extent to which the amplitude of contraction returns to normal after transfer of cells into 
the TC-free medium is also shown. (*P<0.05 compared to control) (ANOVA and 
Student t test). (n=10 early stage; n=11 late stage).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 * 
 * 
 * 
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3.4 Discussion  
It is known that ICP can be complicated by fetal distress, intrauterine death and pre-
term labour. The aetiology of fetal death in ICP is still poorly understood, although it 
has been hypothesized as arrhythmic based on previous studies (Reid et. al, 1976; 
Laatikainen and Tulenheimo, 1984; Laatikainen, 1975; Kramer et. al, 1979). However it 
has been reported that fetal complications occur more frequently in women with ICP if 
the total serum bile acid level is more than 40 µmol/L (Kramer et. al, 1979; Glantz et. 
al, 2004). In this study, tauro-conjugated cholic acid was used as it is one of the 
principal bile acids that are raised in ICP (Laatikainen T 1977). Moreover, cholic acid is 
the most sensitive bile acid for early diagnosis of ICP, as it can rise up to 100-fold. 
Previously, TC has been shown to acutely alter the rhythm and rate of contraction and 
Ca
2+ 
transients in in-vitro model of neonatal rat cardiomyocytes (Gorelik et. al, 2002; 
Williamson et. al, 2001). As experiments on human fetal myocytes are difficult to 
perform due to ethical and logistical reasons, cell culture of myocytes isolated from 
animals such rat is one of the closest available models. 
This study has demonstrated that addition of TC to either mESC-CM or hESC-CM 
caused reduction in the rate and amplitude of contraction, dysregulation of beating, 
calcium overload and disorganization, which were the main characteristics of 
arrhythmia. Moreover, TC-induced arrhythmias were observed in mESC-CM and 
hESC-CM during early stages of differentiation. This susceptibility to TC-induced 
arrhythmia was lost with increasing time of differentiation in culture for both mESC-
CM and hESC-CM. The late stage differentiation of mESC-CMs was almost completely 
resistant to TC, and similarly hESC-CM after 60 days of differentiation lost 
susceptibility to the arrhythmogenic effect of TC. These results are consistent with 
previous findings in rat cardiomyocytes where neonatal cells have been shown to be 
more susceptible to bile acid-induced arrhythmias than adult cells (Gorelik et. al, 2002). 
Consequently, the results support the hypothesis that fetal death in obstetric cholestasis 
is caused by differential sensitivity of the fetal myocardium to bile acid-induced 
arrhythmia as compared to the adult maternal heart.  
At the early stage of differentiation mESC-CM show a variety of patterns of myofibril 
organization with some cells possessing sparse and unorganized structure and others 
showing an indication of A and I bands (Westfall et. al, 1997). Mouse ESC-CM 
continue to differentiate into the intermediate stage where cells become elongated with 
more developed sarcomeres and myofibrils in a process which is similar to the one that 
is consistently observed in in vivo heart development (Westfall et. al, 1997). At the 
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terminal stage of differentiation, the mESC-CM acquire well organized and densely 
packed myofibrils and sarcomeres with well defined A bands, I bands and Z disks 
(Westfall et. al, 1997; Fassler et. al, 1996). Therefore it is reasonable to suggest that 
during the early stage of differentiation of both the mESC-CMs and hESC-CMs, cells 
might resemble early fetal cardiomyocytes with disorganised myofibrils and 
mononucleated cells (Snir et. al, 2003). On the other hand the late stage of 
differentiation (more than 60 days) resembles the adult heart phenotype with organised 
myofibrils and sarcomeres with clearly defined Z-lines and A and I bands (Snir et. al, 
2003). As cardiomyocytes become more mature, they start to lose their proliferative 
activity and that occurs at the same time as they acquire sarcomeric organization (Lopez 
et. al, 1995; Engel et. al, 2005).  
Nevertheless, it has been demonstrated that physical cues such as stretch can 
stimulate sarcomere alignment in immature myocytes. As the cultured ESC-CM do not 
receive such mechanical stimulation, the process of sarcomere alignment in these cells 
occurs relatively slowly. It is well known that in fetal myocytes sarcoplasmic reticulum 
(SR) calcium store is not yet well developed both structurally and functionally. In 
contrast, the adult myocytes possess a well-developed SR calcium store, which 
contributes to the excitation-contraction coupling. This adult phenotype has been 
demonstrated in hESC-CM culture before (Liu et. al, 2007). However, the degree of 
maturation of these cells reported by between groups of researchers differs considerably 
(Liu et. al, 2007; Dolnikov et. al, 2006). The maturation time for hESC-CM has been 
shown to be longer than for mESC-CM, and the maturation of hESC-CM in culture has 
been observed up to 7 months (Harding et. al, 2007). Of course, the gestation periods 
for mouse and human are different (Itzhaki et. al, 2006); nevertheless they are 
comparable based on the morphology of the cells. The definition of early and late stage 
of differentiation for mouse and human ESC-CM are consistent with the published 
literature on the maturation markers. 
The data observed in this study are consistent with previous results on rat neonatal and 
adult cardiomyocytes which showed that the bile acid-induced arrhythmias are Ca
2+ 
related (Gorelik et. al, 2002; Williamson et. al, 2001). In addition, bile acids have been 
demonstrated to increase the intracellular calcium concentration in vascular endothelial 
cells (Nakajima et. al, 2000). Here, the result showed that the TC-induced intracellular 
calcium release is related to desynchronisation of ES-derived cardiomyocyte networks. 
Interestingly, TC effects were more potent on the immature cardiomyocytes and are not 
significantly reversible by washing. However it is not known whether this was the 
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consequence of an irreversible change in conformation of ion channels or whether 
calcium overload damages the cells. In addition, this study has demonstrated that the 
use of the SICM permits recognition and detection of contraction and calcium transients 
of ESC-CM within a mixed population as previously published (Gorelik et. al, 2006). 
This study has demonstrated the sensitivity of cultured ESC-CM during maturation of 
more than 25 days for mouse and 72 days for human. In mESC-CM, the early and 
intermediate stage of differentiation have been reported to have morphology and 
electrophysiology characteristic that is similar to murine fetal cardiomyocytes (Boheler 
et al. 2002). Similarly in early stage of differentiation of hESC-CM, the cells has been 
shown to has morphology and electrophysiology characteristic that is comparable to 
human fetal cardiomyocytes (Mummery et al. 2002). Both mESC-CM and hESC-CM is 
an appropriate invitro model to use as it could provide insight effect of bile acid on fetal 
cardiomyocytes throughout development.  
Overall, the results obtained in here demonstrated that immature ESC-CM, both 
murine and human, are more susceptible to bile acid-induced arrhythmias than adult 
cells and that as the cells progress to a more mature phenotype this effect is lost. Using 
hESC-CM in particular will lead to possibility of understanding of the mechanisms 
underlying choleostatic intrauterine fetal death and to the identification of potential 
therapeutic agents for treating cholestatic intrauterine fetal death.    
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nuclear receptors in bile acid induced arrhythmia in 
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4 Involvement of bile acid transporters, receptors and 
nuclear receptors in bile acid induced arrhythmia in 
neonatal rat cardiomyocytes 
4.1 Introduction 
The intracellular levels of bile acids are tightly regulated as they are potentially 
cytotoxic compounds. This regulation is accomplished by transcriptional regulation of 
genes encoding proteins that play a role in bile acid synthesis, metabolism and transport. 
Bile acids are synthesized from cholesterol in the liver and stored in the gall bladder. 
Upon ingestion of a meal, bile acids are secreted into the duodenum to aid solubilization 
and digestion of dietary cholesterol, lipids and fat soluble vitamins. Bile acids are 
absorbed from the terminal ileum and transported back to the liver by portal venous 
blood. Maintenance of the enterohepatic circulation of bile is important for several 
metabolic functions such as cholesterol metabolism and excretion of potentially toxic 
metabolites and xenobiotics. Apart from regulating their own synthesis and circulation, 
bile acids are also known to regulate various signalling pathways such as cholesterol, 
triglyceride and glucose metabolism. 
In the liver, bile acid uptake from the portal circulation occurs mainly via Na
+
/ 
Taurocholate co-transporting polypeptide (NTCP) and also via Organic Anion 
Transporting Peptides (OATPs) (Trauner & Boyer 2003). Bile acids are then 
transported into the bile canaliculus via ABC transporters such as the bile salt export 
pump (BSEP) , MDR1, MRP1, MRP2 and MRP3. When transported into hepatocytes, 
bile acids can activate several nuclear hormone receptors including farnesoid X receptor 
(FXR) (Pauli-Magnus et al. 2005). FXR is a key bile acid regulator. In the liver, FXR 
works by repressing the expression of CYP7A1, a rate-limiting enzyme in the synthesis 
of bile acids which is partially mediated by short heterodimer partner (SHP) expression 
(Goodwin et al. 2000).  
Recently, bile acids have been identified to be ligands for TGR5 (also known as 
GPBAR1, M-BAR and BG37), a G-protein-coupled receptor (Kawamata et al. 2003). 
Secondary bile acids, such as deoxycholic and lithocholic acid, were reported to be the 
most potent activators of TGR5(Kawamata et al. 2003). TGR5 is ubiquitously expressed 
in vertebrates but its expression levels vary between tissues (Watanabe et al. 2006). The 
effect of TGR5 activation by bile acid is still not fully understood and it is different 
between tissues(Thomas et al. 2008). In the liver, TGR5 is expressed in the sinusoidal 
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endothelial cells and kupffer cells but not detectable in the hepatocytes (Yang et al. 
2007). TGR5 has been associated with immunomodulatory properties of bile acids 
(Kawamata et al. 2003) and some hepatic functions (Vassileva et al. 2006). It is highly 
expressed in the gall bladder where it has been reported to play a role in protection 
against the development of cholesterol gallstones (Thomas et al. 2008). In addition, 
TGR5 has also been found to play role in cell proliferation and apoptosis (Yang et al. 
2007). TGR5 activation was found to increase intracellular cyclic AMP (cAMP) levels 
and activate MAPK kinase pathways (Yang et al. 2007, Keitel et al. 2007).  
To date, the understanding of the bile acid signalling pathways in the liver is increasing 
but little is known about these pathways in cardiomyocyte. Previously, expression of 
FXR, BSEP and MDR3 has been confirmed in human cardiomyocytes cultures (Gorelik 
et al. 2006). Expression of the MRP family of transporters in the heart has been 
suggested to protect the heart against potential toxic substances as they are involved in 
the transport of xenobiotics, however MDR1 and MRP3 are expressed at relatively low 
levels in the heart (Couture et al. 2006).  
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4.2 Gene expression of bile acid transporters and nuclear receptors by qRT-PCR 
in adult rat heart, neonatal rat heart and neonatal rat cardiomyocytes 
 
Firstly, the expression of various transporters that have been previously reported to be 
involved in bile acid transport in other cells such as hepatocytes was studied. As a 
control, bile acid transporter expression in the liver was examined. The relative gene 
expression levels between the adult heart and fetal heart were examined, as these 
differences may contribute to the differences in susceptibility of the fetal heart to bile 
acids. The expression level of transporters was also studied in neonatal cardiomyocytes 
in culture, which are used as a model of the fetal heart and behave in a similar way to 
the fetal heart. Table 4.1 shows the relative level of expression of bile acid transporters 
and nuclear receptors in the neonatal heart and cardiomyocytes compared to the adult 
liver, while Table 4.2 shows the Ct value of mRNA expression of bile acid transporters 
and nuclear receptors in the adult rat liver and neonatal cardiomyocytes. Using qRT-
PCR, the main transporters/receptors mdr2, ntcp, shp and fxr were shown to be 
expressed in adult and fetal rat hearts as well as in rat neonatal cardiomyocytes cultures. 
However, the levels of expression of these genes were quantitatively low compared to 
liver as liver is the main organ for bile acid homeostasis (Table 4.2). The expression of 
mrp2 was significantly lower than the other genes studied. All the genes studied were 
expressed substantially less in adult and fetal hearts and cultured cardiomyocytes than 
in adult liver. Most genes showed similar level of gene expression between adult heart, 
fetal heart and cultured cardiomyocytes. There was no significant difference between 
adult and fetal heart.  
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Gene adult rat heart neonatal rat heart rat neonatal cardiomyocytes 
mdr2 2 3 2 
mrp2 22 20 29 
ntcp 3 4 4 
shp 1.5 2 2 
fxr 5 3 4 
 
Table 4. 1:  Fold decrease in the expression of bile acid transporters and receptors 
in rat adult heart, neonatal heart and neonatal cardiomyocytes as compared to 
adult rat liver.  
Quantitative RT-PCR was performed on RNA extracted from respective tissues (n=3).  
 
 
 
 
Gene Adult rat liver Rat neonatal 
cardiomyocytes 
mdr2 23 29 
mrp2 22 31 
ntcp 21 29 
shp 22 29 
fxr 20 28 
 
Table 4. 2 :Ct values of the expression of bile acid transporters and receptors in rat 
adult liver and neonatal cardiomyocytes.  
Quantitative RT-PCR was performed on RNA extracted from respective tissues (n=3).  
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4.3 Gene expression of bile acid transporters in neonatal rat cardiomyocytes 
treated with TC 
NTCP is known to efficiently transport physiological substrates such as glycine and 
taurine-conjugated bile acid into the liver (Hata et al. 2003, Kramer et al. 1999). Under 
pathophysiological conditions where high levels of bile acids are present, a feedback 
mechanism works to down-regulate NTCP gene transcription and to prevent 
accumulation of cytotoxic bile acids in the liver. The function of this transporter is well 
established in the liver but it is not well studied in cardiomyocytes. In this study, rat 
neonatal cardiomyocytes have been shown to express ntcp using qRT-PCR.  However, 
no significant changes in mRNA transcript were observed between untreated (controls) 
and in cardiomyocytes after 24 hours treatment with 0.1 mM TC (Figure 4.1). 
In the liver, the ATP-binding cassette proteins such as mrp1, mrp2 and mrp3 are known 
to play roles in the efflux of bile acid compounds into the bile canaliculus (Trauner & 
Boyer 2003). Using qRT-PCR, neonatal rat cardiomyocytes have been shown to express 
mrp1, mrp2 and mrp3. As shown in Figure 4.1, administration of 0.1 mM TC did not 
alter the expression of mrp1, mrp2 and mrp3 mRNA in these cells to a significant 
extent.  
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Figure 4. 1: Expression of bile acid transporters in neonatal rat cardiomyocytes 
The graph is showing an averaged expression of bile acid transporters mrp3, ntcp, mrp1, 
and mrp2 in neonatal rat cardiomyocytes pre and post 24 hours TC 0.1 mM treatment. 
(P>0.05, ANOVA, compared to control). (n=3, observations). 
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4.4 Expression of fxr and its target genes in neonatal rat cardiomyocytes 
Fxr expression was further confirmed in neonatal rat cardiomyocytes by 
immunostaining (Figure 4.2), qRT-PCR (Figure 4.3) and western blot analysis (Figure 
4.4).  
Nuclear translocation of fxr was studied as a marker of fxr activation. As shown in 
Figure 4.2, the Huh7 hepatoma cell line was used as a control for the rat neonatal 
cardiomyocytes. Huh7 is known to express fxr and when treated with bile acids the fxr 
translocates into the nucleus (Popowski et al. 2005). Figure 4.2b demonstrated fxr 
translocation following incubation of Huh7 cells with 60 µM CDCA. This effect was 
not observed in neonatal rat cardiomyocytes following incubation with 0.1 - 1.0 mM 
TC. 
Fxr mRNA expression was measured by semi quantitative RT-PCR (qRT-PCR). As 
shown in Table 4, fxr is expressed in primary neonatal rat cardiomyocytes. However, no 
significant changes (p>0.05, ANOVA) in fxr mRNA expression levels were found after 
exposure to 0.1 mM and 1.0 mM TC for 1 hour (Figure 4.3a) and 24 hours (Figure 4.3b) 
. Similarly at a protein level, no significant changes were observed after exposure to 0.1 
mM and 1.0 mM TC after 1 hour (Figure 4.4). In addition, the effect of TC on mRNA 
expression of cyp7a1 and shp (fxr target genes) was also investigated in neonatal rat 
cardiomyocytes. It is known that activation of fxr by bile acids will induce expression of 
shp and repress expression of cyp7a1 in the liver (Thomas et al. 2008). In neonatal rat 
cardiomyocytes this effect upon activation of fxr was not observed following addition of 
0.1 mM TC to the cells (Figure 4.5). 
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Figure 4. 2: Immunostaining for fxr in Huh7 and neonatal rat cardiomyocytes. 
Panel a-b: Hepatoma cell line HUH7 stained for fxr; pre (a) and post (b) treatment with 
60M CDCA for 1 hour (b); Panels c-d: Rat neonatal cardiomyocytes stained for fxr; 
control (c) and after 1 hour incubation with TC 1mM (d). FITC (green) - fxr; DAPI 
(blue) -  nucleus; yellow arrow -  fxr nuclear region staining. (n=3 observations). 
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Figure 4.3: Gene expression of fxr in neonatal rat cardiomyocytes. 
Gene expression of fxr in neonatal rat cardiomyocytes incubated with 0.1 mM and 1.0 
mM of TC for 1 hour (a) and 24 hour (b). No significant changes were observed 
between treatments (P>0.05 compared to control, ANOVA). (observations n=3). 
 
 
 
a) 
b) 
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Figure 4. 4: Protein expression of fxr in neonatal rat cardiomyocytes. 
Representative western blot for fxr in neonatal rat cardiomyocytes treated with 0.1 mM 
and 1.0 mM TC for 1 hour. 
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Figure 4. 5: Gene expression of cyp7a1 and shp in neonatal rat cardiomyocytes. 
Gene expression of (a) cyp7a1and (b) shp in neonatal rat cardiomyocytes after 24 hours 
incubation with 0.1 mM TC (P>0.05 compared to control, ANOVA). 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
b) 
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4.5 FXR agonist and TC-induced arrhythmia in neonatal rat cardiomyocytes  
Previously, TC has been shown to induce arrhythmia in neonatal rat cardiomyocytes 
(Gorelik et al. 2004). In this study, the fxr agonist GW4064 was used to investigate 
whether it could protect cells from the effect of TC. GW4064 is a synthetic non-
steroidal compound that has high affinity for FXR-α and functions as an FXR agonist 
(Maloney et al. 2000). GW4064 has no influence on the contraction of neonatal rat 
cardiomyocytes (Figure 4.6). As shown in Figure 4.6, GW4064 do not protect neonatal 
rat cardiomyocytes from TC –induced arrhythmia.  
 
 
Figure 4.6: Effects of GW4064 and TC on contraction of neonatal rat 
cardiomyocytes 
Fxr agonist GW4064 (0.01mM) does not protect neonatal rat cardiomyocytes from TC-
induced arrhythmia. (* Control vs P<0.05); ANOVA.  n=3 observations). 
 
 
 
 
 
 
 
* 
* 
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4.6 Bile acid uptake in cultured neonatal rat cardiomyocytes 
In order to investigate whether the bile acids act through receptors on the cell surface or 
they are transported into the cytoplasm of cardiomyocytes, a 3H TC influx assay was 
employed. The 3H TC influx assay showed low uptake of 3H TC in neonatal rat 
cardiomyocytes (Figure 4.7a) compared to primary human hepatocytes (Figure 4.7b). 
While hepatocytes showed uptake of 200000 units of TC in the first 20 minutes, 
cardiomyocytes did not take up more than 50 units of radioactive TC even after 120 
minutes incubation. Thus the cellular uptake of 3H TC appeared to be negligible in 
neonatal cardiomyocytes. Primary human hepatocytes were obtained in collaboration 
with Dr. Shadi Abu-Hayyeh from Professor Catherine Williamson‟s group.  
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Figure  4.7: TC influx assay in neonatal rat cardiomyocytes. 
The 3H TC influx assay in neonatal rat cardiomyocytes (a) compared to primary human 
hepatocytes (b). Primary human hepatocytes showed uptake of 200000 units of TC in 
the first 20 minutes, cardiomyocytes did not take up more than 50 units of radioactive 
TC.  
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4.7 Expression and involvement of TGR5 in neonatal rat cardiomyocytes 
As there was no evidence of involvement or interaction of the nuclear receptor fxr with 
bile acids in neonatal cardiomyocytes, fxr was not considered to be of relevance in bile 
acid-induced arrhythmia in the cells. Furthermore, the cellular uptake of radioactive 
labelled TC appeared to be negligible in neonatal cardiomyocytes, which suggests that 
TC may act through a membrane receptor rather than a receptor expressed in cytoplasm. 
Therefore, the study was continued by investigating the involvement of a well-known 
bile acid membrane receptor, TGR5.  
However, no expression of the bile acid-specific TGR5 receptor was detected in 
cardiomyocytes by immunostaining (Figure 4.8). Both liver sections and and liver 
Kupffer cell preparations were used as positive controls for staining, as the liver is 
known to express TGR5 (Keitel et al. 2007). 
In line with these findings, an agonist of TGR5 (oleanolic acid) also did not influence 
cardiomyocyte contraction, nor did it protect against TC-induced arrhythmia (Figure 
4.9). Oleanolic acid is a natural selective TGR5 agonist (Thomas et al. 2008). 
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Figure 4. 8:  Immunostaining of TGR5 in positive control cells and neonatal rat 
cardiomyocytes. 
Top panels: TGR5 immunolocalisation in a liver section and cultured Kupffer cells. 
Bottom panels: Immunostaining for TGR5 in a cluster of neonatal rat cardiomyocytes 
(left and right panels, red colour). Nuclei are stained with Hoechst dye (left panel, blue 
colour). Scale bar 10 m. 
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Figure 4.9: Effect of oleanolic acid and TC on contraction of neonatal rat 
cardiomyocytes. 
TGR5 agonist of Oleanolic acid (OA) agonist (0.01mM) does not protect neonatal rat 
cardiomyocytes from TC-induced arrhythmia. (* Control vs P<0.05); ANOVA, n=3 
observations). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
* 
  123 
4.8 Discussion 
In hepatocytes bile acid uptake from the portal circulation is mediated by bile acid 
transporters, and mainly by the sodium-dependent taurocholate protein (NTCP), while 
the efflux of bile acids from hepatocytes to the bile canaliculus is mediated by 
transporter proteins such as BSEP, MRP3 and the multidrug resistance protein MDR1. 
The expression levels of the promoter-specific repressor shp and the influx transporter 
ntcp are not known in the heart. This study is the first to demonstrate that cardiac cells, 
neonatal rat cardiomyocytes, express ntcp and shp albeit at a significantly lower level 
than in adult liver.  Previously, MDR1 and MRP3 were shown to be expressed in the 
heart at relatively low levels (Couture et al. 2006). Moreover, it has been suggested that 
the expression of MRP family transporters in the heart may protect against potential 
toxic substances, as these transporters are involved in the transport of xenobiotics 
(Couture et al. 2006). The members of the MRP family are expressed on the basolateral 
and canalicular membrane of hepatocytes, and they are important for maintenance of 
normal bile acid homeostasis. Although their expression has been reported in the heart, 
there is little known about their roles. It is also not known whether their expression is 
specific to the cardiomyocytes. Our data in neonatal rat cardiomyocytes are consistent 
with the published data in the heart, i.e. relatively low expression of mdr2 and mrp2. In 
addition, the results obtained show that the transporters ntcp, mrp1, mrp2 and mrp3 are 
not responsive to bile acids treatment as seen in hepatocytes.  
Bile acids are not just a by-product of cholesterol metabolism that regulate circulation 
of cholesterol but they also play roles as signalling molecules and modulate several 
nuclear hormone receptors including FXR. FXR is a member of the steroid nuclear 
receptor family and it is known as a bile acid receptor/regulator (Makishima et al. 1999, 
Parks et al. 1999). FXR regulates the level of a target gene, small heterodimer partner 
(SHP) in hepatocytes. FXR is also known to regulate glucose homeostasis, lipoprotein 
metabolism and other metabolic pathways.  FXR is highly expressed in organs that are 
known to play a role in bile acid homeostasis, such as liver and gut. Surprisingly, FXR 
expression is also high in organs that do not have known functions related to bile acid 
metabolism, including the kidney and adrenal glands (Forman et al. 1995, Otte et al. 
2003, Bishop-Bailey et al. 2004). Low levels of FXR mRNA are present in other 
tissues, including the heart, thymus and spleen (Otte et al. 2003, Huber et al. 2002). The 
role of FXR in the heart is poorly understood.  It has been proposed that it plays a role 
in cardiovascular diseases as it is involved in lipid metabolism and can lower circulating 
triglycerides and cholesterol (Bishop-Bailey et al. 2004, Guo et al. 2006). However, it is 
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not known whether bile acids act as FXR ligands in the heart. Previously, human fetal 
cardiomyocytes have been demonstrated to express BSEP, MDR3 and FXR. In this 
study, fxr was confirmed to be expressed at a RNA and protein level in neonatal rat 
cardiomyocytes. Surprisingly, although the bile acid nuclear receptor fxr is expressed in 
cardiomyocytes, it did not undergo nuclear translocation upon treatment with TC as 
seen in a liver cell line Huh7. In addition, the fxr target genes cyp7a1 and shp are 
expressed in neonatal rat cardiomyocytes at low levels which is consistent with other 
published FXR expression data in the heart (Bishop-Bailey et al. 2004, Forman et al. 
1995) but no significant changes was observed between untreated and TC treated cells. 
Furthermore, the uptake of radioactively labelled TC into these cells was negligible 
compared to hepatocytes, and the fxr receptor agonist GW4064 had no effect on 
contraction. 
This led us to hypothesize that TC may act on cardiomyocytes via membrane receptors. 
We then investigated the involvement of a known bile acid receptor, TGR5 (also known 
as GPBAR1, M-BAR and BG37) in bile acid-induced arrhythmia in cardiomyocytes.  
Bile acids have recently emerged as ligands for TGR5, a member of G-protein-coupled 
receptor (GPCR) (Watanabe et al. 2006). TGR5 has been associated with 
immunomodulatory properties of bile acids (Kawamata et al. 2003) with hepatic 
function (Vassileva et al. 2006). High levels of mRNA for TGR5 were found in human 
placenta and spleen (Kawamata et al. 2003). However the presence of TGR5 in 
cardiomyocytes has not been investigated. This study is the first to demonstrate the lack 
of TGR5 expression in neonatal rat cardiomyocytes by immunostaining. This is in line 
with the published data, which show low levels of TGR5 mRNA expression in the heart 
(Kawamata et al. 2003). 
ICP is a disease of pregnancy associated with harmful effects of bile acids on the fetal 
heart. The molecular mechanisms of this cardiotoxicity have remained elusive. To 
unravel the mechanism of the bile-acid induced arrhythmia, the involvement of bile acid 
transporters and nuclear receptors on the effects bile acid-induced arrhythmia in cardiac 
cells was investigated. This is because in the liver, the enterohepatic circulation is 
regulated by these bile acid transporters and nuclear receptors. However, the findings 
obtained here demonstrated that the main bile acid transporters, TGR5 and FXR, are 
expressed at relatively low levels in the fetal heart and in neonatal cardiomyocyte 
cultures. Moreover, they are not responsive to bile acids in the ways that have been 
reported in the liver. Therefore, it is unlikely they play a role in bile acid-induced 
arrhythmia in cardiomyocytes. 
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5 Bile acid-induced arrhythmia in cardiomyocytes is 
mediated by the muscarinic receptor 
 
5.1 Introduction 
 
In addition to activating nuclear receptors, including the bile acid receptor FXR, bile 
acids are also known to activate the membrane GPCR, TGR5. Similar to TGR5, 
muscarinic receptors are also members of the GPCR family and are known to interact 
with bile acids (Raufman 2003). TGR5 responds to bile acids and is widely studied, 
whereas the bile acid interaction with muscarinic receptors is less studied. Muscarinic 
receptors are known to regulate diverse physiological functions such as cognitive and 
autonomic processes (Wess et al. 2007). Moreover, muscarinic receptors are also 
implicated in the pathophysiology of numerous diseases such as schizophrenia, 
Alzheimer‟s disease and Parkinson‟s disease (Wess et al. 2007). There are five subtypes 
of muscarinic receptor known as M1, M2, M3, M4 and M5. They are expressed in the 
central nervous system and peripheral organs.  In the heart, muscarinic receptors are 
known to play a role in modulation of the rate and force of contraction (Caulfield & 
Birdsall 1998). Acetylcholine is thought to be the only natural ligand for muscarinic 
cholinergic receptors (Raufman 2003). 
 
The first discovery the interaction between bile acids and muscarinic receptor was 
published by Raufman et. al where they showed that taurolithocholic acid is a partial 
agonist of muscarinic receptors (Raufman et al. 1998). In gastric chief cells, an 
interaction of bile acids with M3 muscarinic receptors has been demonstrated to lead to 
an increase in pepsinogen secretion (Raufman et al. 1998). The interaction between bile 
acids and muscarinic receptors was examined further using colon cancer cells that 
express muscarinic receptors and the interaction was shown to cause cell proliferation 
and neoplasia (Raufman et al. 2002). Several studies have provided further evidence of 
the interaction between bile acids and muscarinic receptors (Raufman 2003). In some 
other cell types such as gastrointestinal smooth muscle cells, biliary epithelium, 
vascular endothelium and dermal neurons bile acids have been suggested to interact 
with muscarinic receptors (Raufman 2003). However, little is known about the possible 
action of bile acids on cardiac muscarinic receptors. Up to date, acetylcholine is thought 
  127 
as the only natural ligand for muscarinic cholinergic receptors (Raufman 2003) and it is 
interesting to elucidate the interaction of bile acids with muscarinic receptors. 
 
The muscarinic receptor signalling pathways can be divided into two classes; pertussis 
toxin- insensitive G-protein and pertussis toxin- sensitive G-protein. The pertussis toxin 
insensitive G-protein pathway is mediated by the M1, M3 and M5 muscarinic subtypes 
which preferentially couple to Gq/11- protein and eventually activate phospholipase C 
(Dhein et al. 2001). The pertussis toxin-sensitive G-protein pathway involves the M2 
and M4 muscarinic receptor subtypes which preferentially couple to the Gi/o- protein and 
subsequently result in inhibition of adenylyl cyclase (Dhein et al. 2001). Furthermore, 
bile acids are known to involve in signalling pathways which affect the downstream 
function of cells such as calcium mobilization (Gorelik et al. 2002, Anwer et al. 1988)  
and cyclic AMP (cAMP) synthesis (Keitel et al. 2007) .  
 
In this work, the mechanism of bile acid-induced arrhythmogenesis was extensively 
investigated. The result was that TC is a partial agonist of the muscarinic M2 receptor 
and that its arrhythmogenic effect in neonatal cardiomyocytes is mediated via inhibition 
of cAMP and impairment of contraction.  
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5.2 Taurocholate (TC) is partial agonist of muscarinic receptor 
 
The involvement of the muscarinic receptor in bile acid signalling has been previously 
demonstrated in non-cardiac cells such as gastric chief cells and colon cancer cell lines, 
(Thomas et al. 2008, Raufman 2003). To date, only one study has reported the effect of 
bile acids on cardiac tissue. Khurana et al showed that deoxycholytaurine induced 
vasorelaxation in thoracic aortic rings of rats and mice (Khurana et al. 2005). Since the 
involvement of muscarinic receptors in bile acid signalling has been previously 
suggested in non-cardiac cells (Raufman 2003), this work sought to investigate whether 
TC can bind to and activate the M2 receptor subtype, which is most relevant for 
cardiomyocyte physiology. Cell membranes were obtained from cultured rat neonatal 
cardiomyocytes and then radioligand binding assays were performed with radiolabeled 
muscarinic receptor antagonist (Figure 5.1A). The competitive binding displacement 
experiments of 3H-N-methylscopolamine ([
3
H]NMS) and TC showed that TC can bind 
with an apparent Kd of 17 µM (Fig. 5.1). The competitive binding of [3H]NMS and 
TC was dose dependent. The highest concentration of TC (1 mM) inhibited the specific 
binding of [
3
H]NMS by almost 100 percent.  
The result obtained from neonatal cardiomyocytes was confirmed in CHO-M2. Similar 
to cardiomyocytes, the observations in muscarinic receptor-overexpressing CHO-M2 
cells showed that TC can bind to the muscarinic receptor (Figure 5.1B).  
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A 
 
B 
 
Figure 5. 1: Competitive inhibition curve of 
3
H-NMS binding by TC in neonatal 
rat cardiomyocytes and CHO expressing M2 muscarinic receptor.  
Taurocholate is a partial agonist at the M2 muscarinic receptor. (A) Specific binding of 
TC to muscarinic receptors in cardiomyocyte membranes. Competitive displacement of 
3
H-NMS with TC is shown (Kd values were 17.2 ± 7.3 µM, n=3). (B) Specific binding 
of TC to the CHO-M2 cell membranes. A representative competition displacement 
curve for TC is shown. 
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5.3 The muscarinic receptor is involved in TC-induced arrhythmia 
 
Neonatal rat cardiomyocytes contract spontaneously at a rate of about 106 bpm ± 6.08 
(mean ± SEM, n=5). When TC 0.2 mM and 1 mM were added to the culture medium of 
these cells there was a significant reduction in the rate of contraction, 61.20 bpm ± 5.33 
and 61.32 bpm ± 7.55 (mean ± SD, n=6, P<0.05) respectively (Figure 5.2).  To 
investigate whether the inhibitory effect of TC on cardiomyocyte contraction was 
mediated by muscarinic receptors, pharmacological inhibitors were used. Pre-incubation 
with 500 nM pertussis toxin to inhibit Gi–proteins abolished the negative chronotropic 
effect of TC after 10 minutes treatment with either 0.2 or 1 mM TC (Figure 5.2).  It is 
known that the muscarinic receptor agonist, carbachol, causes reduction of contraction 
in cardiomyocytes (Dhein et al. 2001). Similar to TC, there was a decrease in rate of 
contraction after 100 µM of carbachol treatment and this effect was abolished by 
preincubating with pertussis toxin. (Figure 5.2) 
 
The effect of Cch and TC on cardiomyocytes was further investigated. Cells were 
treated with 0.001 to 1000 µM of either carbachol or TC, respectively, for 10 minutes 
and this showed that carbachol caused a similar reduction in contractility as observed 
with TC but with much higher potency (Figure 5.3). 
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Figure 5.2: Effect of TC and Carbachol on the contraction of neonatal rat 
cardiomyocytes. 
Contraction of neonatal rat cardiomyocytes after treatment with either TC or the 
muscarinic agonist carbachol (Cch) in the presence or absence of the Gi-protein blocker 
pertussis toxin (PTX). (*P<0.05 compared to control);(ANOVA,  n≥3 observations).  
 
* * 
* 
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Figure 5. 3: Dose dependent effect of carbachol (CCh) and taurocholate (TC) on 
the contraction of neonatal rat cardiomyocytes.  
(*P<0.05 compared to control),(ANOVA; n≥3 observations). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
* 
* * 
* 
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5.4 Muscarinic M2 receptor mediates TC effects of cardiac contraction 
 
In order to elucidate which subtypes of the muscarinic receptor are involved in 
muscarinic mediated effects of TC, muscarinic antagonists were used. The muscarinic 
antagonists were specific for each of the muscarinic receptor subtypes, according to 
previously published data (Yang et al. 2002, Dhein et al. 2001). Selective inhibition 
studies showed that 1 µM of the M2 receptor-specific inhibitor methoctramine abolished 
the negative chronotropic effect of TC after 10 minutes treatment with either 0.2 or 1 
mM TC (Fig. 5.4). In contrast, pre-incubation with 1 µM of either the M1 receptor-
specific inhibitor pirenzepine or M3 receptor-specific inhibitor 4-diphenylacetoxy-N-
methylpiperidinemethiodide (4-DAMP) did not inhibit the bile acid-induced reduction 
in contraction (Fig. 5.4), suggesting that M2 receptors are responsible for the effect of 
TC on cardiomyocyte contraction. The result was further confirmed by siRNA 
knockdown of the M2 receptor. The TC effect was observed in cells treated with non-
targeting siRNA (scramble). However, following siRNA knockdown of the M2 receptor 
(siM2) the effect of TC was not observed even with 1.0 mM TC (not significant, p<0.05, 
ANOVA)(Figure 5.5). 
 
The data obtained using optical contractility measurements were further substantiated 
by scanning ion conductance microscopy (SICM). Vertical displacement of 
cardiomyocytes treated with scramble and siM2 were recorded using SICM. Similarly, 
TC caused a reduction in amplitude of cardiomyocyte contraction in scramble-treated 
cells (Figure 5.6) whereas the effect was abolished in cardiomyocytes following 
knockdown of the M2 muscarinic receptor (siM2) with substantially higher rates of 
contraction, even after addition of 1mM TC (Figure 5.7). The amplitude of contraction 
was expressed as percentage in Figure 5.8. The impact of TC was observed and caused 
a reduction up to 65% with TC 1.0 mM whereas after siM2 transfection TC caused a 
reduction only up to 30% which is not significant (p>0.05, ANOVA) (Figure 5.8). 
 
 In order to confirm the knockdown, qRT-PCR was done on cell transfected with 
scramble and siM2. Figure 5.9 showed that transfection of cardiomyocytes with siRNA 
led to a 65% reduction in expression, of mRNA for the M2 muscarinic receptor. 
 
The involvement of the M2 muscarinic receptor in TC-induced arrhythmia was further 
investigated in human ES-derived cardiomyocytes in early stages of differentiation. TC 
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affects the amplitude of contraction, 0.1 mM  (23.2 ± 4.8 bpm) and 1.0 mM (16.3 ± 
1.6bpm( (Figure 5.10), whereas pre-treatment with methoctramine (32 ± 4.2) abolished 
the effect of TC (Figure 5.11) even at higher concentration (1.0 mM). 
 
 
 
 
Figure 5.4: Inhibition analysis of neonatal rat cardiomyocyte contraction. 
Cells were pre-treated with 1 µM of M1 (Pirenzepine), M2 (Methoctramine) or M3 (4-
DAMP) muscarinic receptor antagonists. Cells were then treated with 0.2 mM or 1.0 
mM TC for 10 minutes. (*P<0.05 compared to control); (ANOVA, n≥3 observations). 
* * 
* 
* 
* 
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Figure 5. 5: Effect of M2 muscarinic receptor expression knockdown on 
contraction of neonatal rat cardiomyocytes. 
Cells were transfected for 48 hours with scramble (non-targeting) siRNA or M2 siRNA. 
Cells were then treated with 0.2 mM or 1.0 mM TC for 10 minutes. (*P<0.05 compared 
to control); (ANOVA, n≥3 observations). 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
* 
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Figure 5.6: Representative measurement of the amplitude contraction of Scramble 
(non-targeting) siRNA in neonatal rat cardiomyocytes using SICM. 
Neonatal rat cardiomyocytes transfected with scramble (non-targeting) siRNA showed 
regular contraction and alterations in rhythm and amplitude following TC treatment. 
The extent to which the amplitude of contraction returns to normal after transfer of cells 
into TC-free medium is also shown. (n=6 observations).  
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Figure 5. 7: Representative measurement of the amplitude contraction of siRNA 
knockdown M2 in neonatal rat cardiomyocytes using SICM 
The cardiomyocytes showed regular contraction following siRNA knockdown of M2 
and TC treatment did not have an effect on rhythm of contraction. The extent to which 
the amplitude of contraction returns to normal after transfer of cells into TC-free 
medium is also shown. (n=6 observations). 
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Figure 5. 8: Influence of either 0.2mM or 1.0mM TC on the rate of neonatal rat 
cardiomyocytes contraction after siRNA knockdown of M2 muscarinic receptor 
expression. 
Influence of either 0.2mM or 1.0mM TC on the rate of neonatal rat cardiomyocytes 
contraction after siRNA non-targeting knockdown (scramble) and siRNA knockdown of 
M2 muscarinic receptor expression. This is represented as a percentage (%) of the rate 
of contraction in cells prior to the addition of TC (designated controls). The extent to 
which the rate of contraction returns to normal after transfer of cells into TC-free 
medium is also shown. (*P<0.05 compared to control); (ANOVA n=6 observations). 
 
* 
* 
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Figure 5.9: Efficiency of the siRNA knockdown of the M2 muscarinic receptor as 
confirmed by qRT-PCR. 
 (*P<0.05 compared to control);ANOVA, n=3 observations. 
 
 
 
* * 
* 
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Figure 5. 10: Representative measurement of the amplitude of contraction of in 
human ESCM at an early stage of differentiation (19 days) using SICM. 
The cardiomyocytes showed irregular contraction following TC treatment which has an 
effect on rhythm of contraction. The extent to which the amplitude of contraction 
returns to normal after transfer of cells into TC-free medium is also shown. (n=3 
observations). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control TC 1.0 mM 
TC 0.1 mM Recovery 
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Figure 5. 11: Representative measurement of the amplitude contraction pre and 
post TC in o human ESCM during early differentiation (19 days) using SICM that 
were pre-treated with methoctramine. 
The cardiomyocytes showed regular contraction following treatment with 
methoctramine (M2 muscarinic receptor antagonist) and TC treatment did not have an 
effect on rhythm of contraction in the presence of methoctramine. The extent to which 
the amplitude of contraction returns to normal after transfer of cells into TC-free 
medium is also shown. (n=3 observations). 
 
 
 
 
 
 
 
 
 
 
Control Methoctramine 
Methoctramine + TC 0.1 mM Methoctramine + TC 1.0 mM 
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5.5 TC is a partial agonist at the muscarinic M2 receptor 
 
To explore further the mechanism underlying bile acid-induced arrhythmia in 
cardiomyocytes, the study was extended to investigate whether TC can act as a ligand of 
the M2 receptor and induce downstream signaling responses. It is known that carbachol 
has an inhibitory effect on cAMP production in cardiac myocytes expressing the FRET-
based cAMP sensor Epac2-cAMPs (Nikolaev et al. 2004). Treatment of cells with TC 
led to a decrease in basal cAMP levels which reached its maximum after 1 min, similar 
to the full receptor agonist carbachol. However, the TC-induced inhibition was partial 
(~30%) compared to the effect of carbachol (Figure 6.12), suggesting that TC acts as a 
partial agonist of this receptor.  
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Figure 5. 12: FRET-based cAMP measurements in neonatal rat cardiomyocytes. 
FRET-based cAMP measurements in neonatal rat cardiomyocytes upon stimulation 
with TC show its partial agonistic effect compared to the full agonist carbachol (CCh). 
Isoproterenol (Iso) was used a positive control to stimulate cAMP production. 
Representative experiment, quantification is shown in (B). (*P<0.05 compared to 
control);(ANOVA, n=5 observations). 
 
 
* 
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5.6 Functional involvement of the muscarinic M2 receptor in the TC-induced 
calcium desynchronization 
 
Calcium is known to modulate cellular functions such as proliferation and secretion. 
Bile acids have been reported to increase cellular calcium in hepatocytes (Anwer et al. 
1988) and pancreatic acinar cells (Criddle et al. 2007) in a dose dependent manner. The 
effects of bile acids on cell function have also been suggested to be dependent upon cell 
type. In pancreatic acinar cells, tauroconjugated lithocholic acid has been shown to 
cause induction of calcium signals at concentration 10 times less than in the hepatocyte 
(Gerasimenko et. al, 2006) 
 
The effect of TC on calcium desynchronization and the involvement of M2 receptors in 
this process were investigated in small cardiomyocyte clusters after 72 h of culture 
(~100x100 μm, Figure 5.13). Optical recordings of Ca2+ transient amplitude for 4 
seconds before and after acute exposure (20 min) to 0.2 mM TC showed a complete loss 
of Ca
2+
 transient synchronisation in control clusters and in clusters of cells transfected 
with scrambled siRNA clusters Figure 5.14). In contrast, cell clusters transfected with 
siRNA targeting the M2 receptor, did not show these abnormalities (Figure 5.14). The 
maximum Ca
2+
 peak in the presence of TC scaled to pre-treatment clusters showed a 
significant reduction in control and non-targeting siRNA knockdown (P< 0.05) clusters, 
whereas the reduction in clusters with siM2 transfection was less marked (Table 5.1). In 
addition, the percentage of cells that lost their Ca
2+ 
transient synchronization were 
approximately 67 percent and 70 percent for control and non-targeting siRNA 
knockdown respectively (Table 5.1). In contrast in siM2 transfected cardiomyocytes, 
only about 4 percent of cells loss their Ca
2+ 
transient synchronization (Table 5.1). 
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Figure 5. 13: Overview of a cluster loaded with 5 μg/ml Fluo-4 AM (scale bar = 10 
μm). 
Representative intracellular calcium dynamics recorded in neonatal rat cardiomyocytes. 
 
 
 
Figure 5. 14: Traces of Ca 
2+
 transients recorded in neonatal rat cardiomyocytes. 
Representative traces of Ca 
2+
 transients recorded in cardiomyocytes untreated with TC 
(left panel) and treated with TC (right panel). The top row contains traces from control 
cells, the middle row contains traces from cells transfected with scramble siRNA and 
the bottom row has traces from M2 muscarinic receptor-targeting siRNA treated 
cardiomyocytes. n>5 observations. 
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Condition of cells Percentage of calcium peak 
reduction compared to pre-
treatment (Means ± SEM) 
Loss of Ca 
2+
 Transient 
Synchronization after TC 
(% of cells) 
Control 45.4 ± 11.35 67 
Scrambled siRNA 38.7 ± 3.87 70 
siRNA M2 7.6 ± 0.28 3.57 
 
Table 5.1: Effects of 0.2 mM TC on Ca
2+
 amplitude and percentage of 
desynchronized clusters that are affected. 
Data are normalized to pre-treatment condition and scaled accordingly to dF/F 10%, 
n>5 observations.  
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5.7 Discussion 
 
Emerging evidence indicates that bile acids are signalling molecules that interact with 
nuclear receptors and membrane receptors and subsequently alter cell function (Thomas 
et al. 2008, Nguyen & Bouscarel 2008). However, most of the studies, which are 
focusing on cholesterol, triglyceride and glucose homeostasis, report bile acid 
interactions with nuclear receptors and TGR5, while bile acid signalling through via 
muscarinic receptors is less studies. In 1995, Miyata et. al. reported inhibition of sodium 
taurocholate and deoxycholate-induced gastrin increase in the stomach of rats pre-
treated with atropine (Miyata et al. 1995). This group did not show however a direct 
binding of bile acids to the muscarinic receptor. Raufman et. al observed  that 
lithocholyltaurine (LCT) inhibits binding of [N-methyl-
3
H]scopolamine ([
3
H]NMS)] to 
chief cells from guinea pig stomach and CHO cells expressing the M3 muscarinic 
receptor (Raufman et al. 1998, Raufman et al. 2002). Other studies on bile acid 
interactions with muscarinic receptors showed that they were mediated by M3 
muscarinic subtypes in rat aorta rings (Khurana et al. 2005) and a human colon cancer 
cell line (Cheng & Raufman 2005). 
 
However, the results obtained in this work show that TC can also bind to the M2 
muscarinic receptor subtype, as the increasing concentrations of TC inhibit the binding 
of [
3
H]NMS (a known muscarinic ligand) in CHO cells over-expressing M2 muscarinic 
receptor. In addition the radioligand-binding assay demonstrates that TC can also bind 
to the muscarinic receptor in neonatal rat cardiomyocytes (Figure 6.1). The result 
suggests that TC serves as a partial agonist of this receptor. The partial agonism has 
been confirmed at the level of the second messenger cAMP and in several functional 
assays. Previous studies showed that in ventricular cardiomyocytes M2 muscarinic 
receptors inhibit cAMP production (Stengel et al. 2000).  Our findings are in line with 
these results as we show that TC induces a partial 30 % inhibition of intracellular 
cAMP levels following muscarinic stimulation. (Figure 6.12).  
 
 
Previous studies have shown that TC alters the rate and rhythm of contraction and 
induces abnormal Ca
2+
 dynamics in neonatal rat cardiomyocytes (Gorelik et al. 2002). 
The data obtained in this study was the first to suggest the involvement of muscarinic 
receptors in bile acid induced arrhythmia in neonatal rat cardiomyocytes. This effect 
  148 
was dependent upon Gi-proteins and was blocked by the selective M2 receptor 
antagonist methoctramine and not by M1 and M3 receptor antagonists (Figure 6.2-6.5). 
At the functional level, TC reduced the frequency of contraction with slightly lower 
efficacies compared to carbachol, but the potency of TC in inhibiting contraction was 
much lower (Figure 6.2-6.3 ), supporting the idea of a partial agonist effect. It is known 
that cardiac tissues do express three subtypes of muscarinic receptor (M1, M3 and M2 
receptors) but it has been shown that M2 is dominantly expressed (McKinnon et al. 
1997, Myslivecek 2008). The involvement was then further confirmed in primary 
neonatal rat cardiomyocytes which led to the discovery of M2 muscarinic receptor-TC 
induced arrhythmia as TC-induced arrhythmia was not observed in methoctramine pre-
treated and M2 knockdown cells (Figure 6.4-6.8). In addition, chemical inhibition was 
also observed in human ESC-CM during the early stage of differentiation. It is known 
that the density of cardiac muscarinic receptor decreases with maturation and it has been 
reported to be higher in the heart of neonatal than adult (Howard & Pope 2002).  It is 
known that stimulation of muscarinic M2 receptors within the mammalian heart 
(Caulfield et al. 1993)
,
 (Hulme et al. 1990), modulates pacemaker activity and 
atrioventricular conduction, and directly (in atrium) or indirectly (in ventricles) 
influences the force of contraction (Dhein et al. 2001). Indeed, knocking down M2 
receptors in the mouse abolishes bradycardia in response to carbachol (Stengel et al. 
2000), emphasizing the functional importance of this receptor subtype. Stimulation of 
the heart with the muscarinic receptor agonist carbachol causes a decrease in heart rate 
(i.e. bradycardia) in mice (Stengel et al. 2000). 
 
In addition, siRNA knockdown of the M2 receptor completely abolished the negative 
effect of TC on contraction (Figure 6.6-6.7) and protected against the arrhythmogenic 
effect of TC which was characterized by a pronounced calcium desynchronization 
(Figure 6.14). While it is generally assumed that parasympathetic stimulation of the 
heart acts through the M2 muscarinic acetylcholine receptors to regulate channel activity 
and subsequent cardiac inotropic and chronotopic status, there are several proposed 
mechanisms. The Na
+
 current increases in guinea pig ventricles (Khlkamp 1985) and in 
sheep cardiac purkinje fibers (Iacono & Vassalle 1989) in the presence of either 
acetylcholine or carbachol. Alteration of Na
+
/K
+
 and Na
+
/Ca
2+
 exchanger was also 
proposed to be the M2 agonist stimulant (Iacono & Vassalle 1989, Korth et al. 1988). 
More recently it has been shown that the (PTX)-sensitive Gαi2 coupling protein but not 
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Gαi3 is required for the inhibitory action of muscarinic receptor on cell contractility and 
L-type calcium current in adult ventricular myocytes (Nagata et al. 2000).  
Calcium ions are known as modulators for various cellular functions such as secretion, 
when they act as a second messenger in many cells types. In the heart, calcium ions 
regulate muscle contraction and electric signals to determine heart rhythm. Bile acids 
increase cellular calcium concentration in isolated hepatocytes and other cells, and the 
increase has been reported to be cell-type specific (Raufman 2003). In our work TC-
induced calcium desynchronization was observed in neonatal rat cardiomyocytes 
whereas this effect was not observed in cardiomyocytes following M2-knockdown 
(Figure 5.14 and Table 5.1). The results have demonstrated that TC-induced arrhythmia 
in neonatal rat cardiomyocytes involves the M2 muscarinic signalling pathway.  
 
The structural basis for the specific and functional interaction of TC with muscarinic 
receptors is not fully understood, but it is likely that structural similarity exists between 
TC and other muscarinic receptor agonists. The interaction of these molecules with 
muscarinic receptors is based presumably on similarity in shape and overall charge 
composition between muscarinic receptors, LCT and acetylcholine (Raufman 2003).  
 
Overall, the study has identified partial agonism at the M2 receptor as a novel 
mechanism for bile acid-induced arrhythmia in a model of the fetal heart. Abolishing 
the M2 receptor resulted in elimination of the TC-induced-arrhythmia in cardiac tissue 
as revealed by the mechanical and optical mapping experiments respectively. The 
findings of this study indicate that the muscarininc M2 receptor might be identified as a 
new therapeutic target to prevent fetal arrhythmia associated with cholestasis of 
pregnancy and other diseases. 
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6 Discussion 
Intrahepatic cholestasis (ICP) is a liver disease of pregnancy which can be complicated 
by fetal distress, intrauterine death and pre-term labour (Glantz et al. 2004). The 
aetiology of fetal death in ICP is not well understood, although it has been hypothesized 
to be caused by arrhythmia based on previous studies (Reid et al. 1976, Laatikainen 
1975, Laatikainen & Tulenheimo 1984). It has been reported that fetal complications 
occur more frequently in mothers with total bile acids higher than 40 µmol/L (Kramer 
et. al, 1979; Glantz et. al, 2004). Tauro-conjugated cholic acid was used in this study as 
it is one of the principal bile acids that are raised in ICP and is the most sensitive for 
early diagnosis of ICP (Geenes et. al, 2009(Laatikainen T 1977). The bile acids were 
added at concentrations varying from 0.1 to 1.0mM, which includes clinically relevant 
concentrations. It has been reported that the highest concentration of bile acids in ICP 
patients can be elevated 100 times more than normal pregnancy 5.3 to 6.5 µM (Geenes 
et. al, 2009; Carter, 1991). 
Unexplained stillbirth is a major contributor to perinatal mortality in maternal diseases 
such as diabetes, cholestasis and anti-phospholipid syndrome. It has been proposed that 
deaths may be influenced by the arrhythmogenic effect of maternally derived 
metabolites on the fetal heart, e.g. bile acids in case of ICP (Williamson et al. 2001). 
Most studies of the aetiology of fetal cardiac deaths have been done using animal 
models the as it is difficult to obtain human cardiac tissue. Therefore, experimental 
evidence related to possible mechanisms of fetal death is limited. Animal models are an 
option to investigate fetal cardiac pathology. Animals such as ewes and rats have been 
used to study the influence of maternal cholestasis on the fetus (Campos 1986, Perez et 
al. 1994). However, in animal models several other parameters should be taken into 
account as it could affect the observation of the studies. Consequently, cultured cells 
have been proposed as a replacement for the use of animals in fetal cardiac pathology 
research. The advantage of using primary cultures of neonatal and adult rat 
cardiomyocytes over in vivo animal studies is the reduction in the numbers of animal 
used. Neonatal rat cardiomyocytes is also the closest available model to study the term 
fetal heart. Embryonic stem cells (ESCs) have been shown to be capable of 
differentiation into various cells including cardiomyocytes (Boheler et al. 2002). Human 
embryonic stem cells (hESCs) can differentiate into functionally contracting 
cardiomyocytes. This has raised an opportunity of controlled in vitro studies of 
developing human heart cells (Hescheler et al. 1997, Kehat et al. 2001, Harding et al. 
2007). These studies have demonstrated that primary neonatal rat cardiomyocytes and 
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both human and murine embryonic stem cell-derived cardiomyocytes cultures are 
appropriate as model of fetal heart. 
 
6.1 Stage of differentiation of fetal cardiomyocytes influences susceptibility to 
bile acid-induced dysrhythmias 
Cell culture of myocytes isolated from animals such rat is the closest available model as 
experiments on human fetal myocytes are difficult to perform due to ethical and 
logistical reasons. In addition, findings that will be discussed below demonstrate that 
both human and mouse ESC-CM serve as an appropriate model system to investigate 
intrauterine fetal death in intrahepatic cholestasis (ICP). 
The addition of TC to cardiomyocytes derived from either human embryonic stem cells 
(hESC) or murine embryonic stem cells (mESC) was shown to cause a reduction in the 
rate and amplitude of contraction, desynchronization of calcium and disorganization of 
contraction. All the effects observed fall within the definition of arrhythmia. 
Furthermore, TC-induced arrhythmias were observed in murine ESC-derived 
cardiomyocytes (mESC-CM) and human ESC-derived cardiomyocytes (hESC-CM) 
during early stages of differentiation. However, susceptibility to TC was lost with 
increasing time of differentiation in culture for both mESC-CM and hESC-CM. For 
mESC-CMs, the late stage of differentiation was almost completely resistant to TC, 
while in hESC-CM the susceptibility to TC was observed after 60 days of 
differentiation. These results are in line with previous findings by Gorelik et. al that 
neonatal rat CM are more susceptible to bile acid-induced arrhythmias than adult cells 
(Gorelik et al. 2002). The results presented in this thesis are consistent with the 
hypothesis that fetal death in obstetric cholestasis is caused by differential sensitivity of 
the fetal myocardium to bile acid-induced arrhythmia as compared to the adult maternal 
heart (Al Inizi et al. 2006).  
Mouse ESC-CM show diverse patterns of myofibril organization at different stages of 
differentiation. At the early stage of differentiation mESC-CM show a mixture of 
myofibril organization patterns with some cells possessing a sparse and disorganized 
structure while others showing an indication of A and I bands (Westfall et. al, 1997). At 
the intermediate stage of differentiation mouse ESC-CM become elongated with more 
developed sarcomeres and myofibrils in a process which is similar to the one that is 
consistently observed in heart development in vivo (Westfall et. al, 1997). Over time 
mESC-CM acquire well-organized and densely packed myofibrils and sarcomeres and 
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well defined A bands, I bands and Z disks appear at the terminal stage of differentiation 
(Westfall et. al, 1997; Fassler et. al, 1996). In hESC-CM, at the early stage of 
differentiation the cells contained disorganised myofibrils and are mononucleated (Snir 
et. al, 2003). At the late stage of differentiation (more than 60 days), hESC-CM 
myofibrils become organised and sarcomeres with clearly defined Z-lines and A and I 
bands appear (Snir et. al, 2003). It is known that as cardiomyocytes become more 
mature, they start to lose their proliferative activity which occurs at the same time as 
they acquire sarcomeric organization (Lopez et. al, 1995; Engel et. al, 2005). Hence it is 
reasonable to suggest that both mESC-CMs and hESC-CMs at the early stage of 
differentiation resemble the early fetal cardiomyocyte phenotype whereas at the late 
stage of differentiation they resemble the adult phenotype. 
 In fetal myocytes sarcoplasmic reticulum (SR) calcium stores are not yet well 
developed both structurally and functionally. In contrast, adult myocytes consist of a 
well-developed and functional SR calcium store, which contributes to excitation-
contraction coupling. hESC-CM in culture at the late stage of differentiation has been 
showed to possess well-developed SR (Liu et. al, 2007). As the gestation periods for 
mouse and human are different (Itzhaki et. al, 2006), it is expected that the maturation 
time for hESC-CM is longer than mESC-CM. In this study, hESC-CMs were 
maintained in culture for up to 7 months. Nevertheless, both mESC-CM and hESC-CM 
were found to be comparable based on the morphology of the cells. The cells used in 
this study are consistent with the published literature on the maturation markers for the 
definition of the early and late stages of differentiation for mouse and human ESC-CM 
respectively. In addition, it is also known that physical cues such as stretch can 
stimulate sarcomere alignment in immature myocytes. Since the cultured ESC-CM do 
not receive such mechanical stimulation, the process of sarcomere alignment in these 
cells occurs relatively slow.  
The effect of bile acids on the calcium concentration in hepatocytes has been 
known for years, whereas this effect on other cell types is not well understood. 
Recently, it has been suggested that the bile acid capability to stimulate alterations in 
calcium concentration indicates that calcium toxicity might subsequently contribute to 
bile acid-induced cell damage (Nguyen & Bouscarel 2008). In vascular endothelial 
cells, bile acids have been reported to increase the intracellular calcium concentration 
(Nakajima et. al, 2000). Here we demonstrated that the TC-induced intracellular 
calcium release is related to desynchronisation of ES-derived cardiomyocyte networks. 
Furthermore, the effects of TC were more potent in the immature cardiomyocytes than 
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in the mature cardiomyocytes. Furthermore, this effect cannot be reversed significantly 
by removing TC from the culture medium of immature cardiomyocytes. The 
irreversibility of the TC effect is not well understood. It may be a consequence of a 
conformation change in the ion channel or calcium overload that damages the cells. 
Additionally, this study has shown that SICM allows accurate detection of contraction 
and calcium transients of ESC-CM within a mixed population of cells as has been 
previously published (Gorelik et. al, 2006).  
The sensitivity of cultured ESC-CM during maturation more than 25 days for 
mouse and 72 days for human were studied. Furthermore, the results obtained here 
demonstrated that immature ESC-CM, both murine and human, are more susceptible to 
bile acid-induced arrhythmias than mature/adult cells and as the cells progress to a more 
mature phenotype this effect is lost. Moreover, this study illustrates how the use of 
hESC-CM facilitates the elucidation of the mechanisms underlying fetal arrhythmia. 
That might help as well in finding potential therapeutic agents for treating cholestatic 
intrauterine fetal death.  
6.2 Involvement of bile acid transporters and nuclear receptors in bile acid 
induced arrhythmia in neonatal rat cardiomyocytes 
In ICP, the raised serum level of bile acids has no reported effect on the maternal heart 
but it has been suggested that it is associated with harmful effects of bile acids on the 
fetal heart. The molecular mechanism of the effect of TC on the heart has remained 
elusive. In order to understand the mechanism underlying bile-acid induced arrhythmia, 
investigations were performed to elucidate the role of bile acid transporters and nuclear 
receptors on the effects bile acid-induced arrhythmia in the cardiac cells. In the liver, the 
synthesis and enterohepatic circulation of bile acids is regulated by the bile acid 
transporters and nuclear receptors that were studied. In the hepatocytes bile acid uptake 
from the portal circulation is known to occur via the bile acid transporters, BSEP and 
mainly by the sodium-dependent taurocholate protein (NTCP).  This study has 
demonstrated for the first time that cardiac cells express ntcp. However, the expression 
level is significantly lower than adult rat liver. Other findings suggest that the ntcp is 
not responsive to bile acids in the same way as reported for hepatocytes, which respond 
to the presence of bile acids by downregulation of ntcp expression (Schuetz 2001). It is 
most likely that ntcp does not play a significant role in bile acid-induced arrhythmia in 
neonatal rat cardiomyocytes. 
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In hepatocytes the efflux of bile acids along with other compounds including cholesterol 
and phospholipids into the bile canaliculus is mediated by transporter proteins 
belonging to the multidrug resistance protein family (MRPs). In hepatocytes, the 
members of MRP family are important for the maintenance of the normal bile acid 
homeostasis. Among MRP family members responsible for this function is MRP2. In 
this study, relatively low levels of mdr2 and mrp2 were detected in neonatal rat 
cardiomyocytes which is in line with previous studies in the heart (Couture et al. 2006). 
It has been suggested that these transporters play a role in protecting the heart against 
potential toxic substances, as they are involved in the transport of xenobiotics (Couture 
et al. 2006). Yet, the function of this MRP family transporter in the control of the rate of 
contraction of the heart is not well understood. Furthermore, the findings obtained here 
show that, similar to the transporter ntcp, mrp1, mrp2 and mrp3 are not responsive to 
bile acids treatment in the same manner as seen in hepatocytes. It is plausible to suggest 
that these receptors might not be playing a significant role in the contraction of 
cardiomyocytes and perhaps they are more likely to play other roles such as in drug 
disposition.  
The role of the nuclear receptor FXR in bile acid homeostasis has been widely studied 
((Thomas et al. 2008). FXR is a member of the steroid nuclear receptor family and is 
also known as the key regulator of bile acids homeostasis. It is highly expressed in the 
liver, intestine, kidneys and adrenals (Makishima et al. 1999). In hepatocytes, bile acids 
activate FXR and subsequently regulate the level of target genes such as CYP7A1 
which could be mediated by SHP. Previous studies have shown low levels of FXR 
mRNA in the heart (Otte et al. 2003, Huber et al. 2002). Moreover, it has been proposed 
that FXR might play a role in cardiovascular diseases as it has been shown to be 
involved in lowering circulating triglycerides and cholesterol (Bishop-Bailey et al. 
2004, Guo et al. 2006). However, the role of FXR in the heart is still poorly understood. 
In this study, fxr expression was demonstrated at an mRNA and protein level in 
neonatal rat cardiomyocytes. A previous study has shown that human fetal 
cardiomyocytes also express FXR (Gorelik et al. 2006). Although the fxr receptor is 
present in neonatal rat cardiomyocytes, administration of TC did not activate fxr, this in 
contrast to the effect of bile acids on fxr activation in hepatocytes (Popowski et al. 
2005). Additionally, in this study the expression of the fxr target genes cyp7a1 and shp 
in neonatal rat cardiomyocytes is at a low level. This is consistent with expression data 
for FXR and its target genes in the heart published by others (Bishop-Bailey et al. 2004, 
Forman et al. 1995). Thus, even though cardiomyocytes do express fxr and its target 
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genes, this receptor does not respond to the addition of TC and therefore FXR might 
play a different role in cardiomyocytes. For example, FXR has recently been reported to 
play a role in the development of testis which is not a target organ for bile acids, and 
hence FXR can play a role in regulation of other molecules i.e. steroids (Caron et al. 
2006). Since the FXR receptor is expressed intracellularly, an influx of bile acids into 
the cell is required in order to activate it. However, we found that the uptake of 
radioactively labelled TC into neonatal rat cardiomyocytes was negligible as compared 
to primary human hepatocytes. It is therefore unlikely that the nuclear receptor FXR is 
involved in the mechanism of bile acid-induced arrhythmia. 
As the result indicated that FXR and the hepatic bile acids transporters are unlikely to 
be involved in TC-induced arrhythmia, it was proposed that TC may act on 
cardiomyocytes via plasma membrane receptors on the surface of the cells. Bile acids 
have recently emerged as ligands for TGR5, a member of the G-protein-coupled 
receptor (GPCR) family (Watanabe et al. 2006). TGR5 has been associated with 
immunomodulatory properties of bile acids (Kawamata et al. 2003) and with hepatic 
function (Vassileva et al. 2006). High levels of mRNA for TGR5 were found in human 
placenta and spleen (Kawamata et al. 2003). However, the presence of TGR5 in 
cardiomyocytes has not been investigated. This study is the first to demonstrate the lack 
of TGR5 expression in neonatal rat cardiomyocytes by immunostaining. This is in line 
with the published data, which have shown a low level of mRNA expression in the heart 
(Kawamata et al. 2003). The finding suggests that TGR5 is not likely to be involved in 
TC-induced arrhythmia. 
In this study, relatively low levels of expression have been seen for all the main hepatic 
bile acid transporters and nuclear receptors in the fetal rat heart and in the neonatal rat 
cardiomyocyte cultures compared to adult rat liver. However, their function is likely to 
not be the same in the heart as in hepatocytes and other organs which are responsive to 
bile acids. This finding suggests that it is unlikely that these receptors play a role in the 
bile acid-induced arrhythmia in cardiomyocytes. 
 
6.3 Bile acid-induced arrhythmia in cardiomyocytes is mediated by muscarinic 
receptor 
Bile acids are known to be involved in several physiological processes such as 
regulation of their own synthesis, promotion of lipid digestion, cholesterol metabolism 
and glucose metabolism. Recently, bile acids have been recognized as signalling 
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molecules that interact with either nuclear receptors or membrane receptors and 
subsequently alter cell function (Thomas et al. 2008, Nguyen & Bouscarel 2008). The 
bile acid interactions with FXR and TGR5 are well known and studied, whereas their 
interaction with muscarinic receptors is not well understood and has received very 
limited study.   
The results obtained from this work are the first study to demonstrate that TC inhibits 
binding of labelled [N-methyl-
3
H] scopolamine ([
3
H]NMS)] to neonatal rat 
cardiomyocyte membranes. The binding assay of [N-methyl-
3
H] scopolamine 
([
3
H]NMS)] was repeated on CHO cells-expressing M2 muscarinic receptors, which 
also show increasing concentrations of TC inhibits binding of [
3
H]NMS. This 
observation was the first to suggest that the arrhythmogenic TC effects on neonatal rat 
cardiomyocytes could be mediated by muscarinic receptor. Furthermore, 
pharmacological inhibitions of TC binding to the M2 muscarinic receptors by applying 
chemical M2 blockers and the abolition of M2 receptor expression by siRNA both 
support the evidence that the TC-induced arrhythmia in neonatal rat cardiomyocytes is 
mediated by the M2 muscarinic receptor. In addition, pharmacological inhibition of M2 
muscarinic receptors by methoctramine in human ESC-CM during the early stage of 
differentiation also abolished the effect of TC on contraction. Interestingly, binding of 
labelled bile acid to the M3 receptors has been shown before in the chief cells from the 
stomach as well as in transgenic CHO cells expressing M3 muscarinic receptor 
(Raufman et al. 1998, Raufman et al. 2002). Recent studies also reported that bile acid 
interactions with muscarinic receptors was mediated by M3 muscarinic subtypes rat 
thoracic aortic rings and human colon cancer cell lines. (Khurana et al. 2005) (Cheng & 
Raufman 2005). It is known that the cardiac cells exclusively consist of and express M2 
muscarinic receptor subtypes and these have been shown to be the most functionally 
important muscarinic receptors in modulating the rate of cardiac contraction (Gomeza et 
al. 1999, Caulfield 1993, Maeda et al. 1988, Sharma et al. 1997, Dhein et al. 2001). 
Furthermore, bradycardia does not occur after carbachol treatment of M2 muscarinic 
receptor knockout mice, emphasizing the functional importance of this receptor subtype 
in cardiac cells(Stengel et al. 2000).  
The interaction of bile acids with muscarinic receptors was reported in 1995 by Miyata 
et. al. who demonstrated the inhibition of sodium taurocholate and deoxycholate-
induced gastrin increase in stomach of rat pre-treated with atropine (Miyata et al. 1995). 
Further studies have reported bile acid interactions with muscarinic receptors in CHO 
cells, gastric chief cells and colon cancer cells (Raufman 2003). The interactions have 
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also been reported to contribute to the effects of the downstream cell functions such as 
cell proliferation and reduced phosphorylation of MAPKs ERK1/2 (Cheng & Raufman 
2005, Raufman 2003). In this study, the interaction of TC with the muscarinic receptor 
has been also shown to affect downstream functions of neonatal rat cardiomyocytes. 
Administration of the muscarinic receptor agonist carbachol has been shown to produce 
the same effects as observed with TC. However, the effects of carbachol on the rate and 
rhythm of contraction were observed at a lower concentration compared to TC. This 
finding suggests that TC serves as a partial agonist of the M2 receptor. It is well known 
that stimulation of the heart with the muscarinic receptor agonist carbachol causes a 
decrease in heart rate (i.e. bradycardia) in mice (Stengel et al. 2000). The partial 
agonism of TC was further confirmed at the level of the second messenger cAMP where 
it was inhibited by TC at 30 % compared to carbachol.  In line with other studies, bile 
acids are known to inhibit the cAMP level in several cell types such as hepatocytes 
(Bouscarel et al. 1995) and dermal fibroblasts (Bouscarel et al. 1995). Nevertheless data 
regarding the effect of bile acids on cAMP levels appear to be cell specific as bile acids 
stimulate cAMP synthesis in some cells including cholangiocytes (Alpini et al. 1997).  
Apart from its effect on contraction, TC is also known to induce abnormal Ca
2+
 
dynamics in neonatal rat cardiomyocytes (Gorelik et al. 2002). In the heart calcium ions 
are known to regulate muscle contraction and electric signals to determine heart rhythm 
in the sinus node. Disturbances in cardiac rhythm seem to be a result of abnormalities in 
the impulse initiation, which is directly correlated with calcium influx. In this work, TC 
has been shown to induce calcium desynchronization in neonatal rat cardiomyocytes 
which is mediated by the muscarinic receptor and subsequently leads to arrhythmia. It 
has been reported that muscarinic stimulation can contribute to inhibition of the 
intracellular calcium (ICa) concentration in atrium and ventricle of heart of most species 
(Dhein et al. 2001). It is well known that parasympathetic stimulation of the heart is 
mediated by the M2 muscarinic acetylcholine receptors. Thus, stimulation of muscarinic 
receptors in the heart subsequently might regulate channel activity and cardiac inotropic 
and chronotopic status. To this end, there are numerous tentative mechanisms of this 
stimulation proposed. In the rat, muscarinic receptor stimulation of the ventricles can 
lead to direct negative inotropic effects (McMorn et al. 1993). It is known that in 
ventricular myocytes carbachol increases intracellular Ca
2+ 
transients via M1 muscarinic 
receptor (Sharma et al. 1996) and in guinea pig via the M2 muscarinic receptor (Protas, 
1998). The presence of acetylcholine or carbachol has also been reported to lead to an 
increase in the intracellular Na
+
 current in guinea pig ventricles(Khlkamp 1985) and 
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cardiac purkinje fibers in sheep (Iacono & Vassalle 1989) in the presence of either 
acetylcholine or carbachol. Na
+
/K
+
 and Na
+
/Ca
2+
 exchanger alterations have also been 
proposed to be the M2 agonist activator. (Iacono & Vassalle 1989, Korth et al. 1988).  
The interaction of lithocholyltaurine and muscarinic receptor in gastric chief cells has 
been postulated due to similarity of their molecules to acetylcholine molecule in terms 
of their shape, overall charge composition (Raufman 2003). The specific interaction of 
TC with muscarinic receptors which leads to a functional interaction is not fully 
understood. For future study, crystallography is needed to understand the structures of 
both molecules and the molecular basis of their interaction. 
The present study has identified a novel mechanism for bile acid-induced arrhythmia in 
a model of the fetal heart. Administration of a chemical inhibitor and treatment with 
siRNA for the M2 muscarinic receptor abolished the effect of TC-induced-arrhythmia in 
cardiomyocytes.  The data obtained in the present study suggest that the muscarininc M2 
receptor might be a new therapeutic target to prevent fetal arrhythmia associated with 
cholestasis of pregnancy and other diseases. 
 
6.4 Overall Conclusion 
In conclusion, the study demonstrated that the arrhythmogenic effect of TC in neonatal 
rat cardiomyocytes is most likely to be mediated by partial agonism at the M2 receptor 
whereas bile acids transporters, FXR and TGR5 are unlikely to play a significant role in 
the mechanism of arrhythmia. It is known that stimulation of muscarinic M2 receptors 
within the mammalian heart (Caulfield et al. 1993)
,
(Hulme et al. 1990), modulates 
pacemaker activity and atrioventricular conduction, and directly (in the atrium) or 
indirectly (in the ventricles) influences the force of contraction (Dhein et al. 2001). As 
explained in the previous chapter, the effect of TC was only observed in immature 
cardiomyocytes but not in mature cardiomyocytes. There is no significant difference in 
the expression of muscarinic receptors in the hearts of newborn and adult rats (Nedoma 
et al. 1986). However, the modulation of voltage L-type Ca 
2+ 
channels via the 
muscarinic receptor is different in the fetus and adult. In adult cardiomyocytes, Ca
2+ 
 L- 
type channels are abundant and this is necessary for controlling the Ca
2+ 
influx for Ca
2+ 
-induced Ca
2+ 
 release (CICR), and these channels are directly coupled with M2 
muscarinic receptor via cAMP (Ramesh et al. 1995). In contrast, in fetal 
cardiomyocytes, Ca
2+ 
 L- type channels are less prevalent and contraction  depends upon  
transarcolemmal  Ca
2+ 
 influx rather than Ca
2+ 
 release from sarcoplasma reticulum 
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(SR), as the activity of SR Ca
2+ 
-ATPase is  lower compared to adult cardiomyocytes 
(Ramesh et al. 1995). In addition, in the early stages of cardiomyocytes differentiation, 
signalling via the M2 muscarinic receptor has been reported to show suppression in the 
modulation of L-type Ca 
2+ 
channels (Hescheler & Fleischmann 2002). This might 
explain why immature cardiomyocytes are more susceptible to TC-induced arrhythmia 
than mature cardiomyocytes. It might also explain the phenomenon in ICP where the 
elevated bile acids do not have an effect on the maternal heart but only on the fetal 
heart. The study provides a meaningful explanation for the mechanism underlying ICP-
related stillbirth. It is also likely that similar mechanism exists in other fetal 
arrhythmias. Furthermore, the data reported here indicate that the M2 receptor pathways 
might serve as a promising new therapeutic target for fetal arrhythmia and intrauterine 
death.  
 
6.5 Clinical implications and future research 
As  the present study only dealt with the in vitro cell culture model, in future it would be 
interesting to translate the study into an in vivo model of ICP. Prof. Williamson‟s group 
has developed two murine models of ICP, both of which are cholestatitc in pregnancy. 
One involves feeding 0.5% cholic acid (CA) and the other uses mice deficient in fxr 
(Milona et al. 2010). It has been shown that this mutants have gestational increase in 
bile acids in the serum and hepatocytes, and these changes are more marked in the 
mutants were fed with CA (Milona et al. 2010).  
Previously in Dr.Gorelik‟s group, UDCA has been shown to protect neonatal rat 
cardiomyocytes from the arrhythmogenic effect of TC (Gorelik et al. 2003). 
Ursodeoxycholic acid (UDCA) is a relatively hydrophilic BA that has been used 
effectively to treat a spectrum of cholestatic disorders (Stojakovic 2007, Corpechot 
2008), including ICP (Glantz et al. 2005). UDCA has a variety of actions, including 
upregulation of the expression principal hepatic BA transporters and protection against 
BA-induced apoptosis. It has been shown to improve maternal symptoms and 
biochemical abnormalities in ICP. However, no studies to date have been powered to 
demonstrate whether it protects against the fetal complications. It will be interesting 
analyse how the muscarinic signalling works in the presence of UDCA.  
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